

X-Ray Structure and enzymatic study of a Bacterial NADPH oxidase highlight the activation mechanism of eukaryotic NOX

Reviewed Preprint

Revised by authors after peer review.

About eLife's process

Reviewed preprint version 2

March 12, 2024 (this version)

Reviewed preprint version 1

January 23, 2024

Sent for peer review

November 14, 2023

Posted to preprint server

October 16, 2023

Isabelle Petit-Härtlein, Annelise Vermot, Michel Thépaut, Anne Sophie Humm, Florine Dupeux, Jérôme Dupuy, Vincent Chaptal, José A. Marquez, Susan M.E. Smith , Franck Fieschi 

Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale, Grenoble, France • European Molecular Biology Laboratory (EMBL) Grenoble, 71 Avenue des Martyrs, Grenoble, France • CNRS-Lyon 1 University Laboratory 5086, IBCP, Lyon, France • ALPX S.A.S. 71, Avenue des Martyrs, Grenoble, France • Department of Molecular and Cellular Biology, Kennesaw State University, GA, USA • Institut Universitaire de France (IUF), Paris, France

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

Abstract

NADPH oxidases (NOX) are transmembrane proteins that professionally produce reactive oxygen species (ROS) and are distributed widely in both eukaryotes and prokaryotes. Eukaryotes use the ROS products for innate immune defense and signaling; the seven human isoforms of NOX participate in critical physiological and pathophysiological processes. Recently solved structures of two human NOX isoforms provide much new information, but do not fully elucidate controls on the electron transfer pathway from NAD(P)H substrate through FAD and heme cofactors to the final ROS product. SpNOX, a bacterial NOX homolog from *Streptococcus pneumoniae*, shows robust constitutive activity in detergent solution, making it a good prototype for exploring electron transfer in the NOX family. Here we present crystal structures of wildtype and mutant full-length and dehydrogenase (DH) domain-only constructs of SpNOX. The isolated DH domain acts as a flavin reductase, and both DH and full-length constructs use either NADPH or NADH as substrate. Our data supports hydride transfer from NAD(P)H to FAD as the rate limiting step in electron transfer. Using the DH domain, we demonstrate the role of F397 in allowing access of nicotinamide to the flavin isoalloxazine, while in the full-length construct, we used mutants and flavin analogs to confirm the contribution of both domains to flavin binding observed in the structure. Comparison with homologous enzymes suggests distal heme access may influence the final electron acceptor, while the relative position of DH and TM does not necessarily correlate with activity of a given NOX family member. Based on this comparison, SpNOX appears to be a good model of active NOX2, which allows us to propose an explanation for NOX2's requirement for activation.

eLife assessment

In this manuscript, the authors investigate the properties of prokaryotic NADPH oxidases (NOX) and discuss the implications for NOX regulation and function. The structure of the *S. pneumoniae* Nox protein is an **important** step forward in our understanding of prokaryotic NOX enzymes and the characterization and interpretation are **convincing**. The results will be of interest to structural biologists as well as biochemists focusing on enzymatic functions.

Introduction

NADPH oxidases (NOX) are membranous enzymes that ‘professionally’ produce the reactive oxygen species (ROS) superoxide or H_2O_2 (Vermot et al., 2021 [↗](#)); the ‘professional’ production in NOX contrasts with many other sources of cellular ROS which result from metabolic leaking or byproducts. The first-characterized human enzyme of the NOX family, now called NOX2, has been known since 1978 (Segal and Jones, 1978 [↗](#)), and provided a paradigm of its ROS product as a cytotoxic agent in defense mechanisms. However, from 1999 – 2001, six other isoforms of NOX were discovered: NOX1/3/4/5 and DUOX1/2 (Banfi et al., 2001 [↗](#); De Deken et al., 2000 [↗](#); Dupuy et al., 1999 [↗](#); Geiszt et al., 2000 [↗](#); Kikuchi et al., 2000 [↗](#); Suh et al., 1999 [↗](#)). These other isoforms of NOX function in many tissues and cell types and the ROS they produce play roles beyond cytotoxic defense, as biochemical and signaling agents. In addition to the identification of NOX2 deficiency as the cause of chronic granulomatous disease (Segal and Jones, 1978 [↗](#), 1979 [↗](#)), dysregulation of other NOX family members has since been highlighted in pathophysiologies like hyperthyroidism (De Deken et al., 2000 [↗](#); Dupuy et al., 1999 [↗](#)) and inflammatory bowel diseases along with well-documented participation in normal physiological process like cardiovascular tone regulation (Rajagopalan et al., 1996 [↗](#)), sense of balance (Banfi et al., 2004 [↗](#)), and fertility (Musset et al., 2012 [↗](#)) among others. Interestingly, these integrated processes directly link to multicellularity leading to the belief that true NOXes are found only in multicellular eukaryotes (Lalucque and Silar, 2003 [↗](#)).

The various isoforms display significant diversity in assembly with accessory membrane proteins ($\text{p}22^{\text{phox}}$ for NOX1-4, DUOX1/2 for the corresponding DUOX1/2) or not (NOX5); in phosphorylation-promoted association of cytosolic factors required for activation (NOX 1-3) or not (NOX4-5, DUOX1/2); in the presence of EF hands conferring Ca^{2+} dependence (NOX5, DUOX1/2) or not (NOX1-4); and in the species of ROS produced, superoxide for NOX1-3,5 and H_2O_2 for NOX4 and DUOXs enzymes (Vermot et al., 2021 [↗](#)).

Despite their variety, all NOX family members share a common catalytic core comprised of two conserved domains. The transmembrane (TM) domain belongs to the Ferric Reductase Domain (FRD) superfamily, which consists of six TM helices containing conserved histidines in TM 3 and 5 that chelate up to two heme b cofactors (Zhang et al., 2013 [↗](#)). The cytosolic dehydrogenase (DH) domain belongs to the Ferredoxin NADP⁺ Reductase (FNR) family which has motifs to bind a flavin cofactor and a pyridine dinucleotide NAD(P)H (Taylor et al., 1993 [↗](#)). Thus, the NOX core catalytic domain contains the necessary machinery to move electrons from the electron donor – NADPH – through the flavin and heme cofactors to the ultimate electron acceptor, molecular oxygen, to make the ROS product.

The fusion of the TM (N-terminal) and DH (C-terminal) domains constitutes the conserved architecture for the catalytic subunit of the NOX family members. The widespread appearance of separate FRD and DH domains in prokaryotes motivated a search for prokaryotic NOX homologs.

First, separate *E. coli* FRD and FNR representatives MsrQ and Fre were identified and shown to interact, producing a NOX-like flow of electrons from NADPH to flavin and through the hemes to an electron acceptor (Juillan-Binard et al., 2017 [\[1\]](#)). Another bioinformatic search identified a large number of prokaryotic sequences with fused FRD and FNR domains (Hajjar et al., 2017 [\[2\]](#)). We demonstrated that one such protein from *Streptococcus pneumoniae*, called SpNOX, is a *bona fide* NOX that produces ROS and shares the spectral signature and biochemical hallmarks (resistance to cyanide, inhibition by DPI) of eukaryotic NOX (Hajjar et al., 2017 [\[2\]](#)), although its biological function in *S. pneumoniae* has not yet been determined. These results demonstrate definitively that NOXes also exist in prokaryotes. SpNOX purifies as a monomer and is constitutively active (Hajjar et al., 2017 [\[2\]](#)), so it represents the minimal functional core shared by all NOX family members. Furthermore, unlike eukaryotic NOX family members, it overexpresses well in *E. coli* and retains robust activity in detergent solution. These qualities make SpNOX well suited to structural determination by several methods.

Published crystal structures of separate TM and DH domains of a NOX5 homolog CsNOX from the cyanobacterium *Cylindrospermum stagnale* (Magnani et al., 2017 [\[3\]](#)) provided novel structural information about the NOX family. A low resolution structure of full length SpNOX (Vermot et al., 2020 [\[4\]](#)) provided the first look at the fused TM and DH domains in NOX proteins, while cryo-EM structures of mammalian DUOX1 (Sun, 2020 [\[5\]](#); Wu et al., 2021 [\[6\]](#)) and NOX2 (Liu et al., 2022 [\[7\]](#); Noreng et al., 2022 [\[8\]](#)) furnished important new insights. Still, much remains to be discovered regarding electron transfer, the essential catalytic function of the NOX family. SpNOX thus remains an attractive prototype through which to examine structure/function relationships common to NOX family members.

Here, we obtained X-ray structures of WT and F397W mutant of DH-only, and of a F397W mutant of full-length SpNOX. We combined enzymological and structural characterization to elucidate insights into substrate and cofactor recognition, as well as kinetic and mechanistic aspects of electron transfer for the NOX enzyme family. Comparative analysis of this constitutively active prokaryotic NOX with the previously described human NOX2 and DUOX1 structures provides a molecular explanation NOX2's requirement for an activation step.

Results and Discussion

Production of SpNOX and SpNOX_{DH} domain

SpNOX shares only about 25% identity with the human NOX homologs; nonetheless the NOX family members share several well-conserved motifs identified in eukaryotic NOX by Massari et al (Massari et al., 2022 [\[9\]](#)). Figure S1A shows the logos corresponding to the eukaryotic NOX motifs in (Massari et al., 2022 [\[9\]](#)), but constructed from our alignment containing about half prokaryotic sequences. Other than the motif identified as NADPH3, for which our joint prokaryotic-eukaryotic NOX alignment lacked consensus, SpNOX (and other prokaryotic NOX) recognizably share all the motifs identified by Massari & al (Massari et al., 2022 [\[9\]](#)). The C-terminal motif identified by our alignment includes several residues past the C-terminal end of the motif identified from eukaryotes, indicating the high frequency of additional residues in prokaryotic NOX. A specific acid/base pair (E₂₈₃R₂₈₄ human NOX2 numbering) highly conserved in eukaryotic NOX appears directly after the predicted end of the 6th TM helix (Sharpe et al., 2010 [\[10\]](#)), at the inter-domain hinge (Figure S1B); SpNOX has the similar pair Q₁₈₀K₁₈₁ at this position which prompted us to define K181 as the start of SpNOX_{DH}. A typical SDS-PAGE of purified SpNOX and SpNOX_{DH} is shown in Figure S2A.

Optimization of the SpNOX_{DH} thermostability and activity

SpNOX_{DH} showed a tendency to aggregate, so we investigated buffer conditions to optimize its stability, solubility and activity (Gekko and Timasheff, 1981 [↗](#); Martins de Oliveira et al., 2018 [↗](#)). SpNOX_{DH} thermostability and activity were assessed through wide ranges of salt concentrations (0.05-1M) and glycerol percentage (0-20%). The temperatures of thermal unfolding were determined by nanoDSF and demonstrated a constant improvement of T_m with NaCl concentration and glycerol percentage increases (Figure 1A [↗](#) and 1B [↗](#)). SpNOX_{DH} activity was assessed by reduction of cytochrome *c*. In reactions without NaCl and glycerol, the DH domain efficiently supported cytochrome *c* reduction (Figure 1C [↗](#) and 1D [↗](#)). In contrast to thermal stability, however, SpNOX_{DH} exhibits a dramatic loss of activity with increasing NaCl and glycerol. We generated a 3D surface plot of T_m as a function of NaCl and glycerol with specific activity as color scale (Figure 1E [↗](#)) which allowed us to optimize buffer conditions jointly. The region highlighted by (○) in Figure 1E [↗](#) indicates that at 300mM NaCl and 5% glycerol SpNOX_{DH} exhibits both high activity (5 mol reduced cyt. *c*/s/mol.SpNOX_{DH}) and a good thermostability (melting temperature of 60°C).

We then optimized the pH in order to conjointly maximize the thermostability and the activity of SpNOX_{DH}. Direct comparison of the kinetic parameters of SpNOX_{DH} and SpNOX necessitated identifying a pH that would work well for both constructs. The dependences of SpNOX_{DH} activity (Figure S3A) and stability (Figure S3B), evaluated along a range of pH (respectively 5-7 and 4-9.5) in the presence of 300 mM NaCl 5% glycerol, exhibit a progressive decrease with increasing alkalinity. Like SpNOX_{DH}, the thermostability of SpNOX follows a similar and progressive decrease of T_m with alkalinity (Figure S3B), but in contrast the activity of SpNOX shows an optimum at higher alkalinity (Figure S3A). The two constructs show similar activity at pH 6.5, so we chose this as the pH. Thus, for all experiments in which we compare activity of the full-length SpNOX to the truncated SpNOX_{DH}, we chose a standard buffer of 50mM bis TRIS-propane pH 6.5, 300 mM NaCl, 5% glycerol.

Functional characterization of SpNOX_{DH}

The DH domain of NOXes, including SpNOX, as a homolog of the FNR superfamily, should catalyze the transfer of two electrons from the cytosolic NADPH to the FAD coenzyme; in full length NOX the electrons are then transferred singly to the hemes and across the membrane to molecular O₂. The functionality of the DH domain of SpNOX was evaluated by monitoring the oxidation of NADPH substrate and also by monitoring ferricytochrome *c* reduction which in the absence of the TM domain indicates the capacity of FAD to transfer electrons to soluble O₂. Superoxide generation was assessed in aerobic conditions using SOD-inhibitable ferricytochrome *c* reduction.

Like purified or membrane preparations of both the full length and DH constructs of other NOX family members (Han et al., 2001 [↗](#); Nisimoto et al., 2004 [↗](#), 2010 [↗](#)), SpNOX_{DH} requires supplemental FAD to sustain both superoxide production, which can be observed in the presence of Cyt *c* (Figure 2A [↗](#)), and NADPH oxidation, which can be observed in the absence of Cyt *c* (Figure 2B [↗](#)). The dependence of SpNOX_{DH} on flavin in the oxidation of NADPH was assessed by addition of diphenyliodonium (DPI), a common specific flavoenzyme inhibitor (Nisimoto et al., 2014 [↗](#)), which inhibited the enzyme activity (Figure 2C [↗](#)).

In Figure 2D [↗](#) NADPH oxidation and superoxide generation by SpNOX_{DH} in aerobic conditions was followed simultaneously at both 340 and 550 nm. The addition of superoxide dismutase (SOD) led to a ~40% inhibition of SpNOX_{DH}'s Cyt. *c* reductase activity, confirming that the reduction of Cyt. *c* observed in the system is partly due to O₂^{•−} generation (Figure 2D [↗](#) and Table I). However, the remaining ~60% Cyt. *c* reductase activity suggests direct electron transfer from the FADH₂ produced by the SpNOX_{DH} to the Cyt. *c*. Thus, SpNOX_{DH}, separated from the TM domain, retained the redox properties and sensitivity displayed in the context of the whole SpNOX protein (Hajjar et al., 2017 [↗](#)). The strict requirement of FAD addition for SpNOX_{DH} activity and its μM level of




Figure 1

Buffer optimization for improvement of SpNOXDH thermostability and activity.

(A) Thermal unfolding curves of SpNOXDH (0.2 mg.mL^{-1}) in 50mM B bis TRIS-propane buffer pH 6.5, 300 mM NaCl with various glycerol percentages: 5% (-), 10% (-), 15% (-), 20% (-). (B) Thermal unfolding curves of SpNOXDH (0.2 mg.mL^{-1}) in bis TRIS-propane buffer pH 6.5, 5% glycerol with various NaCl concentrations: 100 mM (-), 200 mM (-), 300 mM (-), 400 mM (-), 500 mM (-), 750 mM (-), 1 M (-). (C) Cytochrome *c* reduction in presence of SpNOXDH (1 μg) NADPH (200 μM) FAD (10 μM) in the standard 50mM bis TRIS-propane buffer at pH 6.5, 300mM NaCl in presence of various glycerol percentages: 0% (-), 5% (-), 10% (-). (D) Cytochrome *c* reductase activity with SpNOXDH (1 μg), NADPH (200 μM), FAD (10 μM), glycerol (5%), in presence of various NaCl concentrations: 0 mM (-), 100 mM (-), 200 mM (-), 400 mM (-), 1 M (-). (E) 3D surface representation of T_m dependence with NaCl concentrations and glycerol percentages. (o) depicts the optimum used for further experiments of this study.




Figure 2

Effect of cyt. c, FAD, SOD and DPI supplementation on SpNOXDH NADPH oxidase activity.

Assays performed with NADPH (200 μ M) and SpNOXDH (1 μ g) in the initial mix. Monitoring of cytochrome c reduction (Cyt.c reductase activity) (A) or NADPH oxidation (flavin reductase activity) (B) along with successive addition of FAD and SOD (A and B) or DPI (C) with Cyt.c (blue trace) or without (grey trace) in the initial mix. (D) Monitoring simultaneously NADPH oxidation (red) and cytochrome c reduction (blue) in presence of SpNOXDH, cytochrome c, NADPH and FAD, addition of SOD is indicated by an arrow. The table presents the molecular specific activity measured for the different compositions of the initial mixture and addition of the multiple reactants.

affinity suggests that the flavin behaves as a co-substrate rather than a prosthetic group. As an isolated domain, SpNOX_{DH} may work as a flavin reductase enzyme (Gaudu et al., 1994 [↗](#); Fieschi et al., 1995 [↗](#); Niviere et al., 1996 [↗](#)), making an interesting parallel with the *E.coli* flavin reductase *fre* (also in the FNR family) which reduces the MsrQ transmembrane component (in the FRD family, like the NOX TM domain, see **Figure 6** [↗](#)) (Caux et al., 2021 [↗](#); Juillan-Binard et al., 2017 [↗](#)).

Comparative flavin recognition properties and activities of SpNOX_{DH} vs SpNOX





To characterize the flavin reductase activity of the DH domain and the relative contributions to FAD binding of the TM and DH domains of SpNOX, we determined the K_m and k_{cat} of SpNOX and SpNOX_{DH} cytochrome *c* reductase activity using flavins FAD, FMN, riboflavin, and lumiflavin (**Table 2** [↗](#)). We observed a progressive loss of affinity for SpNOX as flavin size diminishes, with 263-fold higher affinity for FAD than for lumiflavin (**Table 2** [↗](#)). In contrast, the SpNOX_{DH} retains constant affinity equal to that of lumiflavin (~10μM) regardless of the flavin analog. These results suggest that the isolated DH domain binds to FAD primarily at the isoalloxazine ring of the cofactor, and the addition of ribitol (riboflavin), phosphate groups (FMN), and adenosine nucleotide (FAD) do not further interact significantly with the isolated DH domain. However, the full-length SpNOX appears to interact along the entire length of the FAD cofactor, indicating significant interactions between the FAD and the TM domain. This FAD binding site shared between the TM and DH domains may contribute to the correct placement of the cofactor for electron transfer to the proximal heme. On the other hand, in full length SpNOX the k_{cat} appears to be independent of the flavin derivative used, suggesting that the binding interactions between TM and FAD play no catalytic role and that only the isoalloxazine ring needs to be taken into account for the electron pathway from NADPH to the first heme. Finally, the k_{cat} of full length and DH-only constructs are the same order of magnitude, with ratios around 1 (**Table 2** [↗](#)), showing that the presence (or absence) of the hemes in the TM domain has little effect on the rate. It follows that the reduction of FAD – i.e., hydride transfer from the nicotinamide – is the rate limiting step in the electron transfer from substrate to O₂.

SpNOX uses NADPH and NADH with similar affinity and activity

The typical Michaelis Menten type kinetics parameters of SpNOX and SpNOX_{DH} were obtained for increasing NAD(P)H concentrations (**Table 3** [↗](#)). Full length and DH constructs showed the same order of magnitude affinity to each other for NADPH or NADH as substrate (**Table 3** [↗](#)). Furthermore, the value of 1 for NADPH/NADH affinity for each construct shows that SpNOX does not discriminate significantly between NADPH and NADH; the agreement of two different assays – cytochrome *c* reduction and NADPH oxidation – strengthens this observation. Thus, in SpNOX, the NAD(P)H binding energy arises from interactions just in the DH domain with little contribution from the TM domain of SpNOX. The lack of discrimination of SpNOX between NADH and NADPH represents a significant difference from eukaryotic NOX which strongly select NADPH as substrate. In these experiments that used a range of NAD(P)H concentration, k_{cat} 's of the same order of magnitude for both constructs again supports hydride transfer as the limiting step in NOX electron flow.

Structural characterization of SpNOX and SpNOXDH : mutation of F397

We obtained large hexagonal crystals of SpNOX (See Figure S5) but with poor diffraction power beyond 5 Å, and only 6 % between 3 to 5 Å, with clear anisotropy. We therefore tried stabilizing mutations based on the work of Deng *et al* (Deng et al., 1999 [↗](#)) in pea FNR, homologous to the NOX DH domain. They showed that the FNR C-terminal Y308 stabilizes the isoalloxazine site of the FAD cofactor and regulates access of the NADP⁺ substrate to this site; other works extended the

			
FAD	FMN	Riboflavin	Lumiflavin

	K_m (μM)			k_{cat} (s^{-1})		
	SpNOX	SpNOX _{DH}	K_{mDH}/K_m	SpNOX	SpNOX _{DH}	$k_{\text{catDH}}/k_{\text{cat}}$
FAD	0.049 ± 0.01	12.89 ± 0.69	263	4.68 ± 0.74	6.73 ± 0.74	1.44
FMN	0.92 ± 0.01	7.89 ± 0.48	8.6	3.01 ± 0.04	5.14 ± 0.14	1.70
Riboflavin	8.28 ± 0.01	16.76 ± 1.47	2	7.37 ± 0.38	2.77 ± 0.16	0.38
Lumiflavin	16.56 ± 2.77	15.85 ± 1.07	1	4.67 ± 0.45	4.14 ± 0.11	0.89

Table 2

SpNOX and SpNOXDH affinity for flavins. K_m and k_{cat} of SpNOX and SpNOXDH for FAD, FMN, riboflavin and lumiflavin. K_{mDH}/K_m and $k_{\text{catDH}}/k_{\text{cat}}$ indicate the ratio between K_m s or k_{cat} s measured on the DH domain and on the full-length SpNOX protein. Figure S4 shows the kinetic studies corresponding to the parameters presented here.

Substrat		K_m (μM)			k_{cat} (s^{-1})	
		SpNOX	SpNOX _{DH}		SpNOX	SpNOX _{DH}
		Assays	Cyt.C red	Cyt.C red	Cyt.C red	Cyt.C red
NADPH	WT	41.5 ± 5	106 ± 31	87.89 ± 13	6.42 ± 0.6	5.42 ± 1.15
	<i>F399W</i>	n.d.	86.7 ± 6.5	-	n.d.	9.07 ± 0.5
	F397S	33.76 ± 5	79.3 ± 19.5	-	10.80 ± 0.5	8.29 ± 1.3
NADH	WT	41.81 ± 4.4	133 ± 21	80.27 ± 9.1	3.5 ± 0.2	4.41 ± 0.5
	<i>F399W</i>	n.d.	148.6 ± 46	-	n.d.	8.65 ± 2
	F397S	25.46 ± 2	66.9 ± 10.3	-	10.3 ± 0.4	6.20 ± 0.5
WT NADPH/NADH		1	0.8	0.96	1.8	1.2

Table 3

K_m and K_{cat} using NADPH or NADH as electron donor for the SpNOX WT, F399W and F397S full length constructs or the corresponding versions of the DH domain (SpNOXDH). F399W is in italics to indicate that position 399 is not homologous to the terminal aromatic in FNR; the W mutation at the homologous position, F397W, did not have sufficient activity to perform such analysis and thus does not appear in this table. WT NADPH/NADH is the ratio of the K_m or K_{cat} for NADPH vs NADH. For SpNOXDH WT K_m s were determined by monitoring both Cyt. c reductase activity (at 550 nm) or flavin reductase activity (at 340nm) when reported. The kinetic studies corresponding to the parameters presented here are in Figure S7.

discussion of the importance of this residue to the NOX DH domain (Zhen et al., 1998 [↗](#); Kean et al., 2017 [↗](#)). We reasoned that changing the corresponding residue of SpNOX to W would stabilize FAD binding and inhibit NADPH binding, thereby reducing mobility of the two subdomains relative to each other. Supporting this approach, Magnani et al reported the stabilizing effect in CsNOX of the serendipitous insertion of a Trp that stacks with the FAD isoalloxazine ring (Ceccon et al., 2017 [↗](#); Magnani et al., 2017 [↗](#)). Similarly, we reasoned that changing the corresponding F residue to S would increase NADPH access to FAD, potentially facilitating crystals with NADPH bound.

Based on sequence alignment (Fig. S1), either of two phenylalanine residues in SpNox, F397 and F399, could correspond to the conserved C-terminal residue in FNR. We mutated both positions to tryptophan in the SpNOX_{DH} construct and monitored activity to test their effects. In our standard buffer used for comparing DH with full-length constructs, F399W mutants showed normal activity (Table 3 [↗](#)), while F397W mutants showed no activity (Fig 3 [↗](#)). We interpreted this to mean that W in position 397 prevents hydride transfer by immobile stacking with the isoalloxazine ring of FAD, while W in position 399 has little effect on hydride transfer. These results indicate that F397 of SpNOX corresponds to the terminal Y of FNR.

We subsequently explored mutations of F397 in both full length and DH constructs of SpNOX. The flavin content of purified F397W is much higher than that of WT, while the F397S is not able to retain flavin in its binding site (Figure 3A [↗](#)), consistent with our hypothesis about flavin binding. As displayed in Fig 3B [↗](#), in our standard activity conditions, F397W has little or no activity while F397S shows enhanced activity compared to WT. Increasing the NADPH concentration 10-fold resulted in low but significant activity of the F397W mutant (not shown). These results indicate that the W and S mutations of position 397 do not significantly affect the structural integrity of the SpNOX constructs. We used Michaelis-Menten experiments to test the affinity for both NADPH and NADH of F397S mutants of full-length enzyme and DH constructs; such experiments were not possible with F397W because of its very low activity (Figure 3 [↗](#)). F397S mutants show similar results to WT (Table 3 [↗](#)) in both constructs indicating that S in this position does not greatly impact affinity for either substrate; this mutation produced an increase in k_{cat} for both constructs, consistent with the hypothesis that S in this position provides increased access of substrate to the catalytic site.

High resolution structure of the SpNOX Dehydrogenase domain

The use of the full-length SpNOX F397W construct resulted in about 20% of the crystals produced displaying diffraction limits close to 4 Å, with some crystals showing an anisotropic diffraction between 3 and 3.3 Å in a privileged direction of the crystals, as often observed for membrane proteins (Martin et al., 2023 [↗](#); Robert et al., 2017 [↗](#)). Despite the improvement of the crystal quality, the anisotropy precluded resolution without a good model for molecular replacement. However, the soluble SpNOX_{DH} domain represents more than 50% of the full-length enzyme, making it a suitable model for use in molecular replacement. We obtained some crystals of both SpNOX_{DH} WT and F397W, co-crystallized with FAD. Unfortunately, crystals of the SpNOX F397S mutant with or without NADPH could not be obtained.

De novo resolution at 1.94 Å of SpNOX_{DH} F397W was possible because we co-crystallized in the presence of sodium bromide and collected a bromide-SAD dataset (see methods). To solve the SpNOX_{DH} WT structure, we used the SpNOX_{DH} F397W structure as a model, and achieved 2.5 Å resolution. As expected, SpNOX_{DH} presents a typical fold of the FNR superfamily of reductase domain containing two sub-domains, the FAD-binding domain (FBD) and an NADPH-binding domain (NBD) (Figure 4A [↗](#)). Both WT and F397W SpNOX_{DH} display 3 molecules per asymmetric unit and the two structures are identical. In the asymmetric unit of SpNOX_{DH} WT, one of the three molecules contains no flavin (Figure S8A). In the asymmetric unit of SpNOX_{DH} F397W, all




Figure 3

: Flavin content and activity measurement of full-length SpNOX WT, SpNox F397S and F397W. A)

UV-Visible spectra of SpNOXDH WT, and mutants. Inset) zoom on the 320-500 nm window, a specific spectroscopic feature of the oxidized flavin isoalloxazine ring. B) Reduced cytochrome c was monitored at 550 nm for SpNOX WT (blue), F397W (red), and F397S (green). A no-protein negative control is shown in black. See also Fig.S6 for spectral characterization of full length SpNOX mutants.

molecules of the unit contain a well-defined FAD (Figure S8B). These observations agree with flavin contents observed in solution (**Figure 3A**) and support the hypothesis that the F397W mutant stabilizes FAD binding.

In strong correlation with the affinity data obtained for the flavins shown in **Table 2**, the DH domain mainly interacts with the isoalloxazine ring through polar contacts with the protein backbone and a few residues (P234, F235 and S23) belonging to the conserved FAD-1 binding motif (Massari et al., 2022) (see Figure S1). The DH domain shows almost no contact with the ribitol and adenosine parts of the FAD. With the exception of possible polar contact of the first phosphate group with the backbone of the protein, the rest of the FAD molecule points out into the solvent, in the direction of the missing TM domain (**Figure 4D**).

In the wild type, the isoalloxazine ring is sandwiched between FBD residues P234 and F235 on its *si*-face, and the NBD residue F397 on its *re*-face (**Figure 4D**). Superposition of the different SpNOX_{DH} WT molecules from the crystal asymmetric unit shows that the F397 aromatic ring imperfectly occupies the position in front of the *re*-face of the isoalloxazine ring (**Figure 4B**), with orientation 40° with respect to the plane of the isoalloxazine ring, and distance at 5.3 Å. In contrast (and as predicted from the homologous FNR structure), the tryptophan of the F397W mutation makes an extensive and much tighter parallel π -stacking interaction at a distance of 3.5 Å from the isoalloxazine ring (**Figure 4C**). From these observations, WT SpNOX_{DH} could well behave as a flavin reductase, able to use different flavins as substrate through the sole recognition of the isoalloxazine ring. As **Fig.3A** shows, the F397W mutant may fix the flavin as a cofactor. **Figure 4E** shows the sidechains of both the F and W residue overlaid, on which is superimposed a putative binding mode of NADPH based on the pea FNR structure (Deng et al., 1999). Trp at position 397 appears to preclude access of the nicotinamide to the isoalloxazine, preventing direct hydride transfer. Phe in this position, however, leaves more space in this pocket and the sidechain has more degrees of freedom, making it feasible for the nicotinamide to displace it and transfer hydride to the isoalloxazine. These observations most likely explain the drastic difference of activity between WT and F397W; they probably also explain the enhanced activity observed in the F397S mutant which provides even more space near the isoalloxazine (**Table 3**). The increase of the global k_{cat} in the F397S mutant is an additional argument to support hydride transfer as the limiting step in NOX electron transfer.

Structure of full length SpNOX

The high-resolution model of the DH domain of SpNOX allowed resolution of the anisotropic crystals of full length SpNOX-F397W to 3.6 Å. Small extracellular loops limiting crystal contacts together with intrinsic interdomain flexibility of SpNOX are probably the source of the crystal anisotropy due to subtle variation of packing within the crystals (Fig S9). Like the previously reported structures of the NOX family (Liu et al., 2022; Magnani et al., 2017; Sun, 2020; Wu et al., 2021), the crystallographic model of SpNOX harbors the N-terminal TM domain that encompasses 6 membrane-spanning alpha helices chelating two hemes, and the C-terminal cytosolic DH domain (**Figure 5A**). The density corresponding to the two heme groups is packed in the channel formed by TM helices 2 to 5. The inner and outer heme are respectively coordinated by the imidazole rings of pairs of histidines H69 (TM3)/H129 (TM5) and H82 (TM3)/H142 (TM5), holding them perpendicular to the plane of the membrane (Vermot et al., 2020). The metal-to-metal distance of the two hemes is ~21.5 Å, while the shortest interatomic distance is ~9.8 Å, between the vinyl groups.

As observed in previously solved structures of NOX enzymes (Liu et al., 2022; Magnani et al., 2017; Sun, 2020; Wu et al., 2021), a similar electron transfer relay across the membrane was mapped. SpNOX has 9.2 Å edge-to-edge distance between the isoalloxazine ring to the inner heme; a conserved aromatic residue, Y136, at equal distance from both hemes (6.9 Å), or even F107 also on the pathway to the hemes, could assist the electron transfer between the hemes as previously suggested (Magnani et al., 2017).




Figure 4

Crystal structures of the DH domain of SpNOX WT and F397W. A) Superposition of SpNOXDH WT (pale cyan ribbon, PDB: 8qq5) and SpNOXDH F397W (light blue ribbon, PDB: 8qq1); FAD is shown as sticks colored by atom, side chains of residues in position 397 (respectively F and W), are shown as sticks in the same color as the corresponding ribbon. B) and C) Superposition of the three different molecules of the asymmetric unit of WT SpNOXDH (B) and of SpNOXDH F397W (C), zoomed on the interaction of the isoalloxazine ring with the aromatic residue at position 397. D) Close up of the FAD binding site in SpNOXDH WT; polar contacts are shown with dotted lines. Colors as for A. E) SpNOXDH with the F397 (pale cyan sticks) and W397 (light blue sticks) residues superimposed; FAD as in A; and NADPH (salmon sticks) shown based on a superposition of the pea FNR:NADPH complex (PDB: 1qfz) with SpNOXDH.




Figure 5

Structure of the full length SpNOX. A) overall structure of SpNOX F397W at 3.6 Å with ribbons in the TM colored by helix, hemes (red sticks) and FAD cofactor (colored by atom). B) The FAD binding site; FAD as in A, side chains (sticks) of residues involved are labeled and interactions are indicated by yellow dotted lines. C) Electron pathway from FAD to distal heme; for clarity, the DH domain and TM1 and TM6 are omitted. Two alternative electron pathways are indicated, from FAD to heme (both depicted as in A), through a direct transfer between the hemes (red dotted line) or with a relay between the hemes using either the well conserved aromatic residue Y136, or F107, both at intermediate distance from the hemes (black and orange dotted lines); distances in Å are indicated.

FAD binding site in the full length

SpNOX: role of the D-Loop region

We observed electronic density corresponding to the FAD cofactor at the interface of the DH and TM domain. FAD binding in the full-length construct preserves the π -stacking interaction with W397 and the interactions with F235 and P234 observed in the DH-only structure. In addition, the full-length SpNOX structure shows that the adenine extremity of FAD is packed in a pocket including the amino acid F399 from the DH domain—providing a potential role for this residue—as well as residues from the D-loop of the TM domain. Indeed, Y122 and R126 could stabilize the adenine ring simultaneously. Y122 interacts through π -stacking with the adenine ring (**Figure 5B**). R126 is at a reasonable distance to bridge with the adenine ring and simultaneously a carboxylate of the proximal heme. However, the resolution of the structure makes the accurate positioning of side chains difficult, particularly in this region which displays large electron densities.

To check the validity of our side-chain observations we generated alanine mutants of Y122 and R126 and checked the affinity of several flavins for each mutant (**Figure 5B** and **Table 4**). We determined affinity for NADPH for all mutants; similar affinity in all mutants suggests no effect of these mutations on global enzyme structure (**Table 4**). The results in **Table 4** shows that only the affinity for FAD is impacted by Y122A and R126A, confirming the role of these residues in the interaction with the FAD's adenine ring, which is missing in the other flavins tested. Y122A diminishes FAD affinity by a factor of 6 and R126A by a factor of 23. This latter suggests that R126 is crucial for FAD affinity; possibly the simultaneous interaction between R125 and both heme and flavin (proposed above) could hold the adenine ring in a position to be sandwiched between Y122 on one side and F399 on the other. Surprisingly, while the position corresponding to Y122 is very highly conserved as an aromatic residue in the full NOX enzyme family, the position corresponding to SpNOX R126 shows a difference between eukaryotes and prokaryotes. In eukaryotes, the position corresponding to R126 is very highly conserved as an aromatic, while in prokaryotes it is most often a basic residue, although aromatics are not uncommon. The interactions with the TM domain's D-loop (or lack thereof) provide an explanation for the differences among the affinities of the flavins for the full-length protein (**Table 2**).

Access to the distal heme: diverse situations from prokaryotic to eukaryotic enzymes

The FRD found in NOXs but also in MsrQ and STEAP proteins, transfers electrons from the cytoplasmic to the extracellular side of the cell. Thus, access of the distal heme is essential to the specificity of the electron acceptor and its product. **Figure 6** compares the distal heme access of a panel of FRD-containing proteins from prokaryotes and eukaryotes. From the structures available to date, including the present study, some FRDs (MsrQ, SpNOX and CsNOX) exhibit small extracellular loops and free access to the distal heme (**Fig 6A**), while others (NOX2) have long extracellular loops (**Fig 6A**) and sometimes another extracellular domain (DUOX) (**Fig 6B**) create a cap that limits access. Homology models of both NOX4 (O'Neill et al., 2018) and NOX1 (Ward et al., 2023) also predict similar caps. In NOX with large caps, the distal hemes are deeply masked, implying that O₂ must diffuse into the protein. On the basis of structures, several potential tunnels have been proposed for NOX2 and DUOXs (Liu et al., 2022; Noreng et al., 2022; Sun, 2020; Wu et al., 2021) and for the homology model of NOX1 (Ward et al., 2023). For most of the tunnels identified, bottleneck constriction would require protein dynamics to allow diffusion and the exact pathway for O₂ still remains to be defined. However, a potential entry site with direct access to the distal heme from the lateral side can be seen in the NOXs with large caps (**Figure 6B**). In addition, an internal pocket in close proximity to the distal heme has been proposed as the site of O₂ reduction through an outer sphere electron transfer mechanism. This pocket is characterized in eukaryotic enzymes by a conserved His and Arg involved in O₂ binding and heme interaction; the residues characteristic of the O₂ reducing center in eukaryotic

	FAD		FMN		Riboflavin		NADPH	
	K_m	$\frac{K_m^{mut}}{K_m^{WT}}$	K_m	$\frac{K_m^{mut}}{K_m^{WT}}$	K_m	$\frac{K_m^{mut}}{K_m^{WT}}$	K_m	$\frac{K_m^{mut}}{K_m^{WT}}$
WT	0.06 ± 0.01	-	0.9 ± 0.3	-	6.4 ± 0.2	-	13 ± 0.74	-
Y122A	0.38 ± 0.5	6.4	1.5 ± 0.9	1.7	9.6 ± 0.08	1.5	23.8 ± 0.04	1.8
R126A	3.5 ± 0.33	59,1	2.9 ± 0.48	3.2	6.63 ± 0.38	1.03	24.4 ± 0.45	1.87

Table 4.

Determination of K_m for flavins as a function of the mutations in the D-loop region. Data here were obtained in the optimal buffer for SpNOX rather than the co-optimized buffer for comparing full-length and DH constructs. It has no impact on flavin K_m determination (compare WT line with values from Table2) but K_m of full length SpNOX for NAD(P)H are lower by a factor 2 to 3 compared to the co-optimized buffer. For the corresponding curve see figure S10.

FRD domains of NOX and DUOX enzymes are not conserved in SpNOX. The importance of the conserved His and Arg in the reducing center pocket of eukaryotes are strongly supported by CGD-induced mutations (Cross et al., 1995 [↗](#); Picciocchi et al., 2011 [↗](#); Rae et al., 1998 [↗](#)). A pathological NOX1 variant was used to show that an additional Asn residue, separated from the conserved His by two residues, is necessary for efficient O₂ reduction (Ward et al., 2023 [↗](#)); this Asn is highly conserved in animal NOX (see Helix 3 motif in Fig. S1) but not prokaryotes. Entry site, tunnel size and reducing center pocket location ensure the selectivity to O₂ as unique electron acceptor for NOXs with large caps.


FRD containing proteins with direct access to the distal heme may reflect more versatility with regard to final electron acceptors. MsrQ, to date the only FRD-containing prokaryotic protein with clearly identified physiological function, provides an interesting case. In *E.coli*, MsrQ transfers its electrons to MsrP, a periplasmic methionine sulfoxide reductase, which repairs proteins damaged by methionine oxidation (Gennaris et al., 2015 [↗](#)). The absence of long extracellular loops allows MsrP to dock on MsrQ and to receive electrons directly from the distal heme to its molybdopterin center. Similarly, SpNOX's exposed heme may confer its ability to directly reduce Cyt. *c* (Hajjar et al., 2017 [↗](#)). The physiological functions of neither SpNOX nor CsNOX are known; in addition to their NOX activity, they may use electron acceptors other than O₂.

Domain orientation in SpNOX structure: comparison with other NOX structures

The previous crystal structure of a prokaryotic NOX was in fact two independent structures of the separate TM and DH domains of CsNOX (Magnani et al., 2017 [↗](#)). With the SpNOX structure presented here we provide the first entire prokaryotic NOX structure, affording a view of the orientation of the TM domain relative to the DH. The importance of the relative orientation of the domains in NOX proteins has been underlined as a critical point in the activation and the efficiency of electron transfer (Liu et al., 2022 [↗](#); Wu et al., 2021 [↗](#)). Comparison of the recent structures of an inactive “resting state” NOX2 and of the presumably active “high Ca²⁺ state” DUOX1, emphasized the large 49° rotation of the DH domain of one structure relative to the other. This motion leads to a 12.4 Å movement of the FAD, which was suggested as critical for the activation of the electron transfer (Liu et al., 2022 [↗](#)). Including SpNOX into this movement analysis is all the more interesting given that SpNOX is constitutively active. Here, **Figure 7A** [↗](#) shows that in our SpNOX structure, the relative position of TM vs DH domain is intermediate between the inactive (NOX2) and active (DUOX) structures. **Figure 7B** [↗](#) details the potential intermediate motions of SpNOX: the relative position of SpNOX DH with respect to the inactive state NOX2 DH rotates 13° and translates 5 Å towards the plane of membrane, while the relative position of the high Ca²⁺ “activated” state of DUOX1 DH rotates almost an additional 49° and translates an additional 7.6 Å. SpNOX's domain orientation is much closer to that observed in the NOX2 resting state than that of DUOX1.

The relative positions of the cofactors involved in the first steps of electron transfer are highlighted in **Figure 7C** [↗](#). The distance between hemes in a given FRD domain is invariant; thus, the efficiency of electron transfer depends on two main factors: the distance between the nicotinamide of NAD(P)H and the isoalloxazine ring of FAD, and the distance between the isoalloxazine ring of FAD and the proximal heme. Surprisingly, there is no evident correlation between DH motion from inactive to active state and contraction of the distance between FAD and heme. In fact, this distance actually increases between inactive NOX2 and constitutively active SpNOX, and from SpNOX to ‘activated’ (high Ca²⁺) DUOX. Nonetheless, in all cases these distances, ranging from 7.2 to 10.2 from edge to edge (from methyl group of the flavin ring to the carboxylate of the heme), all remain compatible with biologically relevant electron tunneling probability, calculated as ≤ 14 Å. (Page et al., 1999 [↗](#)).

A Top view of FRD domain containing protein



B Lateral view of FRD domain containing protein




Figure 6

FRD containing proteins, represented as surfaces, and accessory proteins (p22^{phox} and DUOXA1) represented as ribbons. TM2 to TM5 were structurally aligned; all proteins are depicted in the same orientation based on this structural alignment. A) Top (extracellular) views of the TM domains of MsrQ (AlphaFold model: P76343, green), SpNOX (this work, PDB: 8qq7, gray), TM domain of CsNOX (PDB: 5O0t, purple), NOX2/p22^{phox} (PDB: 8gz3, blue) and DUOX1 (PDB: 7d3f, pink) B). Each protein's lateral side view (a 90° rotation from the orientation in A). Black arrow shows potential access to distal heme either from top or from lateral side. Hemes are represented as salmon sticks.




Figure 7

Comparison of domain and cofactor organization in NOX2, SpNOX and hDUOX1.

A) Proteins were superimposed and are shown in identical orientations based on superposition, resting state NOX2 (PDB: 8gz3, gray ribbon), active SpNOX (this work, PDB: 8qq7, green ribbon) and high Ca^{2+} DUOX1 in (PDB: 7d3f, red ribbon), with DH domains in darker color. B) and C) DH domains only are represented in same orientations and color as in A. In B, angle and translation from NOX2 to SpNOXDH are indicated. In C, angle and translation from SpNOXDH to DUOX1 are indicated. D) Cofactors necessary for electron transfer are shown as sticks, in identical orientations as in A-C, with distances indicated. In SpNOX the sidechain of Trp397 is shown and the distance to FAD isoalloxazine ring indicated. For DUOX1, NADPH is shown and the distance of nicotinamide to the isoalloxazine indicated.

These observations led us to question the paradigm that switching between resting and activated states requires DH motion. The lack of DH motion between the low and the high Ca^{2+} state human DUOX1 structures adds further hesitation. The DH domains of these two structures superimpose with a RMSD of 0.246 Å, and the FAD and NADPH of these structures also superimpose perfectly. The distance between the nicotinamide ring of the NADPH and the isoalloxazine ring of the FAD even in the activated DUOX1 structure is surprisingly large for efficient hydride transfer (**Figure 7C**). In line with conclusions from DH homologs (Deng et al., 1999; Hermoso et al., 2002), our data (**Table 3**, **Figures 3** and **7**) suggests that the SpNOX F397W sidechain represents the position that would be occupied by the nicotinamide ring of NADPH. The distance between the Trp397 sidechain and the isoalloxazine ring of FAD in our structure is 3.3 Å, similar to the corresponding distance of these moieties in homologous DH domains and suitable for hydride transfer. In the case of DUOX1, it has been suggested (Wu et al., 2021) that to enhance hydride transfer, the “high- Ca^{2+} activated” state requires ‘tensing’ of the DH from a relaxed orientation, which can be envisioned as the relative motion of the NBD subdomain (containing NADPH) toward the FBD (containing FAD), rather than a large swing or translation of the entire DH domain relative to the TM domain.

These considerations suggest that differences in relative domain orientations in NOXes might represent isoform specificity rather than intermediate activation states. If so, these differences and those of the cofactor distances could fine tune the electron transfer properties and resulting efficiency of ROS production, linking the isoform with its physiological context. In this context, the impact of the lipid environment on domain orientation is suggested by longstanding observations of lipid effects on NOX activity (Koshkin and Pick, 1993; Shpungin et al., 1989) and by the observation of a lipid in the murine DUOX structure that mediates the interaction between the TM and DH domain through a direct connection with the phospho-ADP-ribose part of the NADPH (Sun, 2020). Structures solved in detergent like ours presented here may be released from interaction with the membrane, increasing flexibility. The question of what happens in NOX2 –whether DH tensing, domain motion, or something else – remains elusive and awaits further structural characterization. In any case the SpNOX domain orientation presented here makes it a rather close model of human NOX2.

A Close-up view of NOX’s NAD(P)H binding domains vs the FNR gold standard

The striking difference in distance between NADPH and FAD at the active site (**Figure 7C**) parallels a structural difference between NOX2 and DUOX1 on one hand, and SpNOX on the other. Here we use the well-characterized FNR structure as a basis of comparison for DH domains. The NADPH binding groove has characteristic motifs universally conserved in DH domains (Piubelli et al., 2000) (motifs NADPH1 and NADPH4 in Figure S1); these motifs provide specific contacts with the NADPH ligand, while the critical aromatic in the C-terminal motif is important for FAD stabilization and apparently displaced by NADPH binding (Deng et al., 1999; Kean et al., 2017). In FNR, the position of the NADPH1 and NADPH4 motifs – representative of the full binding groove for NADPH – are separated from the flavin binding site by a narrow space (**Figure 8** top left), while in DUOX1 the corresponding space is much wider (**Figure 8**, top right). Superposition of the four DH domains makes it clear that in SpNOX the distance between the binding grooves for the two ligands is short, like in FNR (**Figure 8** middle left), while the distance between the ligand grooves in NOX2 is longer, like in DUOX1 (**Figure 8**, middle right). NADPH-binding residues of FNR are mostly conserved in SpNOX (see Figure S11), while the two Arg residues that interact with the 2’-phosphate of NADPH in DUOX 1 are conserved in NOX2, although the side chain of one of those (R446) is not visible in the CryoEM structure of NOX2 (**Figure 8**, bottom left).




Figure 8

Comparison of FNR domains and their putative NADPH binding sites.

Top, pea FNR (PDB: 1qfz), DUOX1 domain (PDB: 7d3f) in complex with NADPH. Middle, SpNOX DH domain (PDB: 8qq7) and NOX2 DH domain (PDB: 8gz3). Bottom, SpNOX DH is represented with the NADPH from pea FNR after superposition of those proteins; NOX2 DH is represented with the NADPH from DUOX1 after superposition of those proteins. Arg residues conserved between DUOX1 and NOX2 are highlighted using CPK colors, side chain of R446 is not defined in NOX2 CryoEM structure. In top and middle line, pale yellow and lime patches represent NADPH motifs 1 and 4, respectively (see figure S1). Assuming that NADPH binding implies movement of F397, residues ³⁹⁷FKF³⁹⁹ have been omitted in the SpNOX DH surface to increase clarity and visibility of NAD(P)H binding groove.

Although the SpNOX and NOX2 structures lack NADPH, superposition produces an excellent picture of the location of the NADPH in these proteins. **Figure 8** (bottom) shows that when the proteins are superimposed, the NADPH from pea FNR fits extremely well into the NADPH binding groove of SpNOX and reproduces the short distance between nicotinamide and isoalloxazine seen in FNR. Similarly, the superimposed DUOX1 NADPH fits very well into the corresponding binding groove of NOX2. Even this crude docking with no energy minimization leaves little doubt about the overall NADPH position in SpNOX and NOX2. Our functional characterization of mutants in position 397 strongly support the picture presented here. Of course, new structures for NOX2 and SpNOX in complex with NAD(P)H would be a welcome addition to confirm these observations.

Taking into account the similar interdomain organization and comparable electron pathways (**Figure 7D**) of SpNOX and NOX2, the different topology at the interface of their respective FBD and NBD subdomains would explain the switch from an inactive conformation of NOX2 in its resting state to a constitutively active conformation of SpNOX. This idea is consistent with the idea that electron transfer in the high Ca^{2+} -state DUOX1 structure may require a ‘tensing’ motion that brings the two subdomains, and hence their ligand binding grooves, closer together (Wu et al., 2021). The mechanism by which the inactive resting state of NOX2 changes to active, and how this situation fits with the activated state of the DUOX1 structure, remains to be elucidated.

Conclusion

The important roles of NOX in human, animal, and plant health and disease explain the field’s focus on eukaryotic NOX. However, prokaryotic NOX’s advantages in production and handling offer opportunities to decipher structural and mechanistic details relevant to the whole family (eg. (Magnani et al., 2017; Vermot et al., 2020)). We present here extensive enzymological characterization of SpNOX activity and also new structural information on both full-length enzyme and the isolated DH. First, the particular effort to optimize conditions for SpNOX_{DH} allowed the investigation of the first step of NOX electron transport, hydride transfer from NAD(P)H to FAD (**Figure 2** and Table I). We showed that NADPH and NADH are equivalent electron donors for SpNOX, constituting a significant difference from eukaryotic NOX. Comparison with the full length SpNOX demonstrates that NAD(P)H binding is largely independent from the TM domain, at least in our conditions in which SpNOX is solubilized in LMNG detergent. Comparison of k_{cat} obtained from both constructs suggests that the hydride transfer from NAD(P)H to FAD is the rate limiting step in the overall NOX reaction (**Table 3**). Structural and functional characterization of WT and mutant F397W and F397S highlight the critical role of the aromatic at 397: Phe provides flavin isoalloxazine ring interaction and stabilization and also properties that allow entrance of the nicotinamide ring to the active site, similar to the mechanism long accepted in FNR family domains. Parallel analysis of flavin analogs using both DH and full length SpNOX shows that the DH domain alone has no selectivity for flavin type. SpNOX, on the other hand, displays a marked selectivity for FAD with affinity at the nM level, indicating binding contribution from the TM domain. This is supported by interactions visible in the entire SpNOX structure, and a related mutational analysis, highlighting the role of the D-Loop region in the interaction with the adenine ring of the flavin (**Figure 5B**).

Structural comparison of NOX structures indicates that accessibility of the distal heme of SpNOX and CsNOX may reflect plasticity in the final electron acceptor, while the inaccessibility of other NOXes may enforce O_2 as a substrate (**Figure 6**). On the other hand, this comparison also generates a new conundrum, how to explain hydride transfer in activated states of NOX. SpNOX shares similar domain organization with NOX2, and the orientations and distances between cofactors in the electron transfer pathway are similar (Fig S12 for overlay of both structures). Surprisingly, DUOX1 domain organization and cofactor distances are quite different, raising the possibility that domain organization is isoform specific. Considering the constitutive activity of SpNOX, we believe that the electron pathway as organized in NOX2 is poised for electron transfer, and that the difference in position of the NADPH binding groove could explain the difference between active and inactive states. The “high Ca^{2+} ” activated state of DUOX1 also displays the

distant binding groove suggesting that an additional step might be required to reach an efficient active state. Rather than a global repositioning of the DH, activation of NOX2 may require an internal rearrangement within the DH that brings the NADPH groove closer to the FAD site; a similar rearrangement may be necessary for electron transfer in activated DUOX1. Conformational change within the DH may agree with a previous study concluding that p67^{phox}, which activates NOX2, regulates hydride transfer from NADPH to the FAD rather than NADPH binding. (Nisimoto et al., 1999 [\[1\]](#)). In this view, the assembly of p67^{phox} with the DH could promote the required rearrangement within the DH domain. However, the resting state of NOX2 has been reported to resist initial binding of NADPH (Liu et al., 2022 [\[2\]](#)). This could be a second level of control for NOX2.

During the review process of this work, another group published a pre-print presenting several CryoEM structures of SpNOX (Dubach et al., 2023 [\[3\]](#)). Remarkably, considering the small size of the protein and its solubilization in detergent, they solved several structures from 2.33 to 2.75 Å resolution. Their high-resolution in the TM domain allowed them to improve the orientation of the adenine part of FAD and of the distal heme. However, apart from these adjustments, their Cryo-EM and our crystal structures are essentially the same (residue Y122 of the D loop is stabilizing the adenine from FAD, the distances between the cofactors are the same as well as the access to the active site or the distal heme). The work of (Dubach et al., 2023 [\[3\]](#)) includes both functional data and additional structural data that complements ours. For example, they mutated F107, one of the potential aromatic relays for the electron transfer between the hemes. This mutation did not produce any functional impact, supporting the idea of a direct electron transfer from the proximal to the distal heme, although only simultaneous F107 and Y136 mutations would definitively close the interheme “relay” possibility. An important contribution of their Cryo-EM work includes structures of SpNOX with bound NAD(P)H; these fully validate the binding site we anticipated (Fig S11), and confirm the critical roles of residue K250, S348 and Y353 in NAD(P)H binding. In addition, these structures highlight the capacity of the active site to accommodate the F397 side chain, the nicotinamide ring and the flavin ring within the groove where hydride transfer should occur. Their structures document the role of F397 in positioning the nicotinamide core within this groove and in controlling hydride transfer, since the F sidechain is located between the flavin and nicotinamide rings. In one of the NADPH-containing structures, they used a F397A mutation, which mimics the situation in which the F sidechain has moved out from between the nicotinamide and flavin rings, to trap a nicotinamide conformation productive for hydride transfer, approaching 3.6 Å from the isoalloxazine ring. These data are fully consistent with our enzymatic and structural characterization of F397 mutants. Altogether both our structures and theirs strongly support the critical role of F397 in the tuning of the hydride transfer mechanism. Taken together, the observations from both the Cryo-EM and our crystal structures of SpNOX reinforce the need for close proximity of the NADPH and FAD binding grooves for hydride transfer, exemplified in this constitutively active enzyme; this in turn supports our hypothesis, presented herein, that the activated state of *eukaryotic* NOX requires a specific relative motion of the NBD toward the FBD to achieve a productive topology in the DH domain.

In conclusion, SpNOX seems to be a good model of an activated form of NOX2. The molecular tools and structures provided in this work will allow further investigations to understand additional molecular features at work in those fascinating NOX enzymes.

Materials & Methods

Structure-based sequence alignment

A large set of 549 NOX homolog sequences distributed about evenly between prokaryotes and eukaryotes, was aligned using MAFFT (Katoh et al., 2019 [\[4\]](#)). The sequences were split into transmembrane (TM) and dehydrogenase (DH) domains identified by homology and including 30

overlapping residues between the domains. Each domain was realigned separately with Promals3D (Pei et al., 2008 [\[link\]](#)). The TM alignment was constrained to the crystal structure of CsNOX TM domain (5O0T) while the DH alignment was constrained to the crystal structure of CsNOX DH domain (5O0X) and DH domain homologs 1GJR, 1FNB, 1GVH, 2EIX, 3A1F; all other parameters were at default values. The resulting multiple alignments were inspected in Jalview (Waterhouse et al., 2009 [\[link\]](#)); those with missing secondary structural elements or with unusually large insertions were removed and remaining sequences were pruned to 91 % (TM domain) or 95 % (DH domain) identity. The final sequence sets (172 sequences of TM and 207 sequences of DH domain) were realigned in Promals3D with default parameters and the same structural constraints specified above. Logos of subsequences of the full alignment were created in WebLogo (Crooks et al., 2004 [\[link\]](#)).

Cloning of SpNOX, SpNOX_{DH} WT, F397S and F397W

The synthetic SpNOX gene optimized for expression in *E. coli* including a polyhistidine tag and thrombin cleavage site at its N-terminus was amplified *via* PCR and subcloned into pET-30b (Novagen) between the NdeI/ BamHI sites (Vermot et al., 2020 [\[link\]](#)).

The expression vector encoding His-tagged SpNOX_{DH} - aa 181-417 of full-length SpNOX - was obtained from SpNOX by site-directed mutagenesis according to the manufacturer's protocol (QuikChange® Lightning Site-Directed Mutagenesis Kit, Agilent), using forward primer 5'GTCTGGTCCCGCTGGCAGTAAATTAGCTTCCGTATCTGGG3' and reverse primer 5'CCCAGATACGGAAAGCTAATTTACTGCCACGCGGGACCAGAC3'. F397S or F397W mutants of SpNOX and SpNOX_{DH} were created using forward primer 5'ACGGAAGTCTACGAAGGCTCTAAATTCAAATGAGAATTCGAGC3' and reverse primer 5'GCTCGAATTCTCATTTGAATTTAGAGCCTTCGTAGATCAGTTCCGT3' for F397S or forward primer 5'CGGAAGTCTACGAAGGCTGGAAATTCAAATGAGAATTCGAGC3' and reverse primer 5'CTCGAATTCTCATTTGAATTTCCAGCCTTCGTAGATCAGTTCCGT3' for F397W. We retain the nomenclature 'F397x' for these mutations in both SpNOX and SpNOX_{DH} constructs, although in SpNOX_{DH} construct that residue is actually in position 217.

Production of SpNOX, SpNOX_{DH} WT, F397S and F397W

The expression of SpNOX WT, F397S and F397W was performed as described in (Vermot et al., 2020 [\[link\]](#)) for the full-length WT SpNOX.

The DH-only domain proteins SpNOX_{DH} WT, -F397S and -F397W were over-expressed in *E. coli* BL21(DE3) using TB medium supplemented with 50 µg.ml⁻¹ kanamycine. At culture OD₆₀₀ = 1, expression was induced by the addition of 0.5 mM IPTG and the culture was grown overnight at 18 °C. Cells were harvested by centrifugation (5000g, 20 min, 4°C) and stored at -20°C. The purification procedure described below is the final optimized version for SpNOX_{DH} stabilization. The pellet was resuspended in lysis buffer (50 mM TRIS pH7, 1M NaCl, 10 mM Imidazole and 5% glycerol) supplemented with deoxyribonuclease and a mix of protease inhibitors (chymostatin, leupeptin, antipain, pepstatin at 1µg.ml⁻¹, aprotinin at 5 µg/ml), disrupted by sonication, and cleared by centrifugation at 4°C (18500 rpm, JA-25.50 Beckman, 20 min.). The clarified extract was purified on a 4 ml His60 Ni-IDA Superflow resin (Ozyme) previously equilibrated in high salt buffer (HS buffer; 50 mM TRIS pH7, 1M NaCl, 10 mM Imidazole and 5% glycerol). After an extensive wash (20 column volumes, HS buffer), the protein was eluted with 50 mM TRIS pH7, 1M NaCl, 300 mM Imidazole and 5% glycerol and the buffer was exchanged against a stabilization buffer (50 mM Bis-TRIS propane pH6.5, 0.3M NaCl, 5% glycerol) *via* gravity using a desalting column (PD10 ref. 17-0851-01, GE Healthcare). The selected fractions were pooled and loaded onto a Superdex75 size exclusion chromatography (GE Healthcare) equilibrated in the same buffer. The protein was eluted as a monomer and concentrated by ultrafiltration (10 kDa centrifugal filter unit, Amicon).

The protein purity was checked on SDS-PAGE and the concentration was determined by UV-visible spectroscopy using respectively $\epsilon_{280\text{nm}} = 24870 \text{ M}^{-1} \cdot \text{cm}^{-1}$ for SpNOX_{DH} WT and SpNOX_{DH} F397S or $\epsilon_{280\text{nm}} = 30370 \text{ M}^{-1} \cdot \text{cm}^{-1}$ for SpNOX_{DH} F397W respectively.

Thermostability assays for SpNOX_{DH} stability improvement

Thermal stability assays were performed using a Prometheus NT.48 nanoDSF instrument (NanoTemper Inc., Germany). 50 μl of sample per condition were prepared to perform experiments in triplicates using standard-treated glass capillaries. The excitation at 280 nm was optimized to yield emission intensities of intrinsic fluorescence at 330 and 350 nm, in the absence of heat gradient, in the range of 5000 to 16,000 A.U. The temperature gradient was set to an increase of 1 $^{\circ}\text{C}/\text{min}$ in a range from 20 $^{\circ}\text{C}$ to 95 $^{\circ}\text{C}$. Protein unfolding was measured by detecting the temperature-dependent change in the ratio of fluorescence emission at 350 nm vs 330 nm. Samples used for testing pH impact on stability were done by diluting 10 times concentrated SpNOX_{DH} solution (2 $\text{mg} \cdot \text{ml}^{-1}$) to a 0.2 $\text{mg} \cdot \text{ml}^{-1}$ protein solution in the following 0.1 M buffers depending on the tested pH: citric acid buffer for pH 4, 5, 5.5 and 6; sodium acetate for pH 4.5; bis TRIS-propane for pH 6.5 and 8, Pipes for pH 7; TRIS for pH 7 and 7.5; Bicine buffer for pH 9 and CAPS buffer for pH 9.5.

Activity Assay on Purified SpNOX and SpNOX_{DH} Domain

The activity of the purified DH domain was measured under aerobic conditions following simultaneously the oxidation of NAD(P)H (decrease of absorbance at 340 nm, $\epsilon = 6.22 \text{ M}^{-1} \cdot \text{cm}^{-1}$) and the reduction of cytochrome *c* (increase of absorbance at 550 nm, $\epsilon = 21.1 \text{ M}^{-1} \cdot \text{cm}^{-1}$), as a function of time, using a Cary 50 UV-visible spectrophotometer (Varian).

A typical assay was as follows: 50 mM bis TRIS-propane pH 6.5, 0.003% LMNG supplemented with 200 μM NADPH, 300 mM NaCl, and 5% glycerol, was added to a 2 mm quartz cuvette. Then 0.5 $\mu\text{g} \cdot \text{ml}^{-1}$ SpNOX_{DH} (final) and 10 μM FAD (final) were added, mixing after each addition. For Cyt *c* reductase assay, 100 μM cytochrome *c* was added prior to the addition of the protein. Final assay volume was 500 μl . When full length SpNOX was used alone, not in parallel study with SpNOX_{DH}, we used a buffer optimized for activity of the full length enzyme: Tris pH 7, 300 mM NaCl, and 0.003% LMNG.

The inhibition of superoxide production was verified by addition of DPI at a final concentration of 50 μM or Superoxide dismutase (10U) to the reaction mixture after a sufficient time to allow the slope to be characterized in the presence or absence of the inhibitor.

Data analysis of thermostability and activity assays

The results from thermostability and activity assays were analyzed simultaneously using the JMP® statistical software (Version 13.0. SAS Institute Inc., Cary, NC, 1989-2019) to plot 2D contour plots of T_m and activity as a function of salt concentrations and glycerol. The median of triplicates was used to compute the graphs, and linear interpolations were done between measurement points to fill the graphs. A 2D linear interpolation was performed on thermostability and activity results as a function of pH and salt concentration using Python® to produce a 3D figure.

Michaelis-Menten kinetic analysis for SpNOX and SpNOX_{DH}

All chemicals and reagents were purchased from Sigma Aldrich. Various NAD(P)H concentrations were obtained by serial dilutions from the saturating NAD(P)H solution in triplicate in a 96-well (flat bottom) Greiner microplate (equilibrated at 25 $^{\circ}\text{C}$). The reaction was initiated (at 25 $^{\circ}\text{C}$) by injection of a mixture of the stabilization buffer (50 mM bis TRIS-propane pH6.5, 300 mM NaCl, 10 μM FAD, 5% glycerol and 0,025 mM LMNG) containing SpNOX_{DH} (250 ng) and cytochrome *c* (100 μM , final concentration) or (50 mM Tris pH 7, 300 mM NaCl, 10 μM FAD and 0,025 mM LMNG)

containing SpNOX (250 ng) and cytochrome *c* (100 μ M, final concentration) and the absorbance at 550 nm was recorded within 3 minutes using a monochromator multimode microplate reader (Clariostar, BMG Labtech) after orbital shaking. Michaelis-Menten saturation curves of SpNOX, initial apparent velocities as a function of NAD(P)H concentration, K_m (μ M), and k_{cat} (s^{-1}) were determined with Prism® software. We determined the kinetic parameters for all flavin analogs using a similar procedure, holding NAD(P)H concentration constant at 200 μ M and varying the flavin concentrations; similarly, kinetic parameters of SpNOX_{DH} were determined for NAD(P)H based on NAD(P)H oxidation by monitoring the absorbance at 340 nm within 3 minutes. Affinity is formally described by K_d , but in the text we use K_m as a “relevant approximation of affinity” (Srinivasan, 2022 [↗](#)).

Crystallization of SpNOX DH domains

Crystallization experiments were carried out at the High Throughput Crystallization Laboratory (HTX Lab) at EMBL Grenoble using automated protocols (Cornaciu et al., 2021 [↗](#); Dimasi et al., 2007 [↗](#); Dupeux et al., 2011 [↗](#); Mariaule et al., 2014 [↗](#)). SpNOX_{DH} and SpNOX_{DH} F397W were concentrated to 15 mg.mL⁻¹. The crystallization experiments were carried out using the sitting-drop vapor-diffusion method with a crystallization robot (Mosquito, SPTLabtech). 0.1 μ L of protein solution and 0.1 μ L of reservoir were mixed to equilibrate against 45 μ L reservoir solution at 20°C in 96-well CrystalDirect plates (MiTeGen) and automatically imaged in RockImager robot (Formulatrix). Initially, commercially available screening kits from NeXtal (Classic-suite, PEGs, JCSG) and Molecular Dimension (MemTrans, MemMeso, MemGold, PACT, Morpheus) were used to identify initial crystallization conditions that were optimized in subsequent experiments. Optimal crystals of SpNOX_{DH} grew in crystallization drops with precipitant conditions of 35% PEG-MME500, 0.1M Sodium Citrate pH5. Optimal crystals of SpNOX_{DH}F397W grew in crystallization drops with precipitant condition composed of 17% to 20% w/v PEG3350, 0.1M Bis-TRIS propane pH 6.5 and 0.2 M Sodium bromide. Crystals of SpNOX_{DH} WT and SpNOX_{DH} F397W typically appeared after 24h and reached full size in 7 days with dimensions of respectively 100 $\times$ 20 $\times$ 10 μ m³ and 80 $\times$ 30 $\times$ 20 μ m³. Automated high-throughput crystal cryo-cooling and harvesting were performed with CrystalDirect™ Technology (Cipriani et al., 2012 [↗](#); Márquez and Cipriani, 2014 [↗](#); Zander et al., 2016 [↗](#)).

Data collection and structural solution of SpNOX DH F397W

A bromide-SAD dataset was collected at the macromolecular crystallography beamline ID30B of the European Synchrotron radiation facility, equipped with Pilatus3 6M detector (McCarthy et al., 2018 [↗](#)). The wavelength was set above the Br K-edge at 0.9184 Å in order to maximize the anomalous signal, and a highly redundant data set at a resolution of 1.94 Å, including 7200 images with 0.05 degrees oscillation, was collected.

Data processing was performed by the GrenADES parallelproc pipeline (Monaco et al., 2013 [↗](#)) that is based on XDS (Kabsch, 2010 [↗](#)) and scaled using aimless (Evans and Murshudov, 2013 [↗](#)) from the CCP4-suite (Winn et al., 2011 [↗](#)). Attempts to solve the structure with the molecular replacement method using homologous models failed. Therefore, we experimentally solved the structure by the SAD method, using the bromide anomalous dispersion signal from crystals grown in presence of 0.2M sodium bromide. Experimental phasing and initial model building was performed using CRANK2 (Skubák and Pannu, 2013 [↗](#)). The final model was obtained by successive rounds of manual and automated refinement using the programs REFMAC (Murshudov et al., 1997 [↗](#)), and BUSTER (Bricogne, n.d.). Crystallographic data statistics are presented in Table S1. The PDB deposition code for the SpNOX_{DH} F397W is 8qq1.

Data collection and structural solution of SpNOX DH WT

X-ray diffraction data were collected at ID30A-1/MASSIF-1 beamline at ESRF Grenoble (Bowler et al., 2015 [DOI](#)). A highly redundant data set at a resolution of 2.4 Å, including 3600 images with 0.1 degrees oscillation, was collected. The structure of SpNOX DH WT was solved at a 2.4 Å resolution by molecular replacement using the coordinates of the chain A of SpNOX DH F397W variant structure (PDB 8qq1) as a search template in Molrep searching for 3 mol/a.u. The initial solution was evaluated using COOT (Emsley et al., 2010 [DOI](#)) revealing no major clashes and good global packing with contacts between chains and classical size solvent channels. The final model was obtained by successive rounds of refinement using the programs REFMAC (Murshudov et al., 1997 [DOI](#)) and manual construction using COOT (Emsley et al., 2010 [DOI](#)). Crystallographic data statistics are presented in Table S1. The PDB deposition code for the SpNOX_{DH} WT is 8qq5.

Crystallization, Data Collection, and Processing of full length SpNOX

SpNOX F397W at 4.04 mg.mL⁻¹ in 50 mM TRIS pH 7, 300 mM NaCl, 0.025 mM LMNG, 0.01 mM FAD was crystallized in 30.5% PEG 300, 0.15 M Li₂SO₄, 0.15 M NaCl and 0.1 M MES pH 6, using the vapor diffusion method in a 6 µL protein sample plus 6 µL of well hanging drop at 20°C. Hexagonal brick-red crystals were obtained, mounted on mesh litho-loops and flash frozen in native conditions in liquid nitrogen. X-ray diffraction data were collected at ID30A-1/MASSIF-1 beamline at ESRF Grenoble (Bowler et al., 2015 [DOI](#)). A dataset of 1800 images was collected with an oscillation range of 0.2° per image and an exposure time of 1.699 s and a crystal to detector distance refined to 500.9 mm. As observed for many membrane protein crystals (Martin et al., 2023 [DOI](#); Robert et al., 2017 [DOI](#)), the data collected were very anisotropic going to 3.2 Å resolution in the strongest diffracting direction. After data processing the dataset was finally cut at 3.6 Å to ensure sufficient completeness in the highest resolution shell. Inclusion of further data only resulted in more noise without obvious gain in 2mFo-DFc electron density. Data were initially processed using the program XDS as spherical to the highest resolution possible (3.2 Å) even though spherical statistics were not usable. Staraniso analysis for diffraction anisotropy (staraniso@globalphasing.org) revealed that completeness was 85.4% in the highest resolution shell, therefore revealing that all the data collectable for this crystal had been collected. Data was cut at the diffraction limits suggested by the Staraniso server using only the first 1000 images.

Phases were solved by molecular replacement using PHASER (McCoy et al., 2007 [DOI](#)), on amplitudes, with data corrected for anisotropy using Staraniso. The search models were the high-resolution DH domain (PDB 8qq5) and a model of the transmembrane domain obtained using PROMALS3D (Pei et al., 2008 [DOI](#)) and I-TASSER (Yang and Zhang, 2015 [DOI](#)) on the basis of multiple sequence alignment of NOX homologs and validated by structural alignment on CsNOX (Vermot et al., 2020 [DOI](#)). The molecular replacement solution was achieved with placing the DH domain first, followed by the TM domain, yielding LLG=91.8 and TFZ=10.9. The phasing resulted in a model with one molecule of SpNOX in the asymmetric unit and the space group P6₄22. Crystal packing generation showed a sensible solution (classic type II packing of membrane protein and no clash), showing good density for the DH domain and clearly identifiable transmembrane helices, representing a typical initial anisotropic low-resolution map for a membrane protein solved by molecular replacement.

The resulting model was not biologically possible with an obvious error in the positioning of the transmembrane domain, which was inverted by 180° around the longitudinal axis. A new transmembrane domain model was generated on the basis of a sequence alignment between CsNOX and SpNOX and the use of CHAINSAW (CCP4). A new molecular replacement with PHASER (McCoy et al., 2007 [DOI](#)) without modification of the DH domain position resulted in a new orientation of transmembrane domain, which was biologically compatible. Fo-Fc map of the model harbored two positive peaks at 6.1 χτ and 3.6 χτ corresponding to the position of proximal and distal hemes, respectively, sandwiched between two key histidine residues, allowing the sequence

assignment of the TM domain. Iterative manual building in COOT (Emsley et al., 2010 [↗](#)) and LORESTR pipeline (Kovalevskiy et al., 2016 [↗](#)), using TLS (5-183 for TM domain and 184-399 for DH domain) allowed large repositioning of some α -helices of transmembrane domain. A final comparison of a SpNOX model generated with AlphaFold (Jumper et al., 2021 [↗](#)) drove the repositioning of some loops and some sequence shifts in transmembrane helices not associated with hemes. Final refinement was made with the help of ISOLDE (Croll, 2018 [↗](#)) and LORESTR, ramachandran and rotamers outliers were corrected, yielding a final model with R = 26.2% and Rfree = 32.0% that was deposited in the Protein Data Bank under the PDB accession code 8qq7. Crystallographic data statistics are presented in Table S1. The PDB deposition code for the SpNOX F397W is 8qq7.

Acknowledgements

Funding for the automated crystallography pipelines at EMBL Grenoble was provided by the grants and iNEXT Discovery (*grant agreement* ID 871037) and Fragment Screen (*grant agreement ID: 101094131*) funded by the European Commission and through Instruct-ERIC. We want to thank the EMBL-ESRF Joint Structural Biology Group (JSBG) and in particular Andrew McCarthy for access and support in the use of MX beam lines at the ESRF. This work used the platforms of the Grenoble Instruct center (UMS 3518 CNRS-CEA-UJF-EMBL) with support from FRISBI (ANR-10-INSB-0502) and GRAL (ANR-10-LABX-49-01) within the Grenoble Partnership for Structural Biology. This work was supported by the French Agence Nationale de la Recherche Bandit Project (ANR17-CE11-0013) to F.F., A.V., I.P.-H., M.T. and J.D. A.V. was supported through the Emergence program from the Univ. Grenoble Alpes; S.M.E.S. was supported by an invited professorship from Univ. Grenoble-Alpes and through Emergence partner Kennesaw State University.

Author contributions

Isabelle Petit-Härtlein, Annelise Vermot, Conceptualization, Validation, Investigation, Visualization, Writing - Original Draft; Michel Thépaut, Anne Sophie Humm, Florine Dupeux, Formal analysis, Investigation, Data Curation; Jérôme Dupuy, Funding acquisition; Vincent Chaptal, Methodology, Formal analysis, Writing -Review & Editing; José A. Marquez, Methodology, Formal analysis, Writing -Review & Editing, Supervision; Susan M.E. Smith, Conceptualization, Formal analysis, Visualization, Supervision, Writing - Original Draft; Franck Fieschi Conceptualization, Formal analysis, Writing - Original Draft, Visualization, Supervision, Funding acquisition, Project administration.

Additional files

Supplementary file: contains complementary data about the enzymatic and structural characterization of SpNOX described in this article, as well as additional analysis (structural comparison, sequence motif, etc.)

Data availability: X-Ray structure with atomic coordinates of the SpNOX_{DH} F397W, SpNOX_{DH} WT and full length SpNOX F397W have been deposited in the PDB under the ID codes PDB: 8qq1, 8qq5, 8qq7 respectively

References

- Banfi B, Malgrange B, Knisz J, Steger K, Dubois-Dauphin M, Krause KH. (2004) **NOX3, a superoxide-generating NADPH oxidase of the inner ear** *The Journal of biological chemistry* **279**:46065–46072
- Banfi B, Molnar G, Maturana A, Steger K, Hegedus B, Demaurex N, Krause KH. (2001) **A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes** *The Journal of biological chemistry* **276**:37594–37601
- Bowler MW *et al.* (2015) **MASSIF-1: a beamline dedicated to the fully automatic characterization and data collection from crystals of biological macromolecules** *J Synchrotron Rad* **22**:1540–1547 <https://doi.org/10.1107/S1600577515016604>
- Bricogne Bricogne. n.d. **BUSTER version X.Y.Z.** Cambridge, United Kingdom: Global Phasing Ltd.
- Caux C *et al.* (2021) **Membrane-Bound Flavocytochrome MsrQ Is a Substrate of the Flavin Reductase Fre in Escherichia coli** *ACS Chem Biol* <https://doi.org/10.1021/acscchembio.1c00613>
- Ceccon M, Millana Fananas E, Massari M, Mattevi A, Magnani F. (2017) **Engineering stability in NADPH oxidases: A common strategy for enzyme production** *Molecular Membrane Biology* **34**:67–76 <https://doi.org/10.1080/09687688.2018.1535141>
- Cipriani F, Röwer M, Landret C, Zander U, Felisaz F, Márquez JA. (2012) **CrystalDirect: a new method for automated crystal harvesting based on laser-induced photoablation of thin films** *Acta Cryst D* **68**:1393–1399 <https://doi.org/10.1107/S0907444912031459>
- Cornaciu I *et al.* (2021) **The Automated Crystallography Pipelines at the EMBL HTX Facility in Grenoble** *JoVE (Journal of Visualized Experiments)* **e 62491** <https://doi.org/10.3791/62491>
- Croll TI. (2018) **ISOLDE : a physically realistic environment for model building into low-resolution electron-density maps** *Acta Crystallogr D Struct Biol* **74**:519–530 <https://doi.org/10.1107/S2059798318002425>
- Crooks GE, Hon G, Chandonia J-M, Brenner SE. (2004) **WebLogo: A Sequence Logo Generator** *Genome Res* **14**:1188–1190 <https://doi.org/10.1101/gr.849004>
- Cross AR, Heyworth PG, Rae J, Curnutte JT. (1995) **A Variant X-linked Chronic Granulomatous Disease Patient (X91+) with Partially Functional Cytochrome b** *Journal of Biological Chemistry* **270**:8194–8200 <https://doi.org/10.1074/jbc.270.14.8194>
- De Deken X, Wang D, Many M-C, Costagliola S, Libert F, Vassart G, Dumont JE, Miot F. (2000) **Cloning of Two Human Thyroid cDNAs Encoding New Members of the NADPH Oxidase Family** *Journal of Biological Chemistry* **275**:23227–23233 <https://doi.org/10.1074/jbc.M000916200>

- Deng Z, Aliverti A, Zanetti G, Arakaki AK, Ottado J, Orellano EG, Calcaterra NB, Ceccarelli EA, Carrillo N, Karplus PA. (1999) **A productive NADP⁺ binding mode of ferredoxin-NADP⁺ reductase revealed by protein engineering and crystallographic studies** *Nature structural biology* **6**:847–853 <https://doi.org/10.1038/12307>
- Dimasi N, Flot D, Dupeux F, Márquez JA. (2007) **Expression, crystallization and X-ray data collection from microcrystals of the extracellular domain of the human inhibitory receptor expressed on myeloid cells IREM-1** *Acta Cryst F* **63**:204–208 <https://doi.org/10.1107/S1744309107004903>
- Dubach VR, San Segundo-Acosta P, Murphy BJ. (2023) **Structural and mechanistic insights into *Streptococcus pneumoniae* NADPH oxidase (preprint)** *BioRxiv* <https://doi.org/10.1101/2023.10.17.562464>
- Dupeux F, Röwer M, Seroul G, Blot D, Márquez JA. (2011) **A thermal stability assay can help to estimate the crystallization likelihood of biological samples** *Acta Crystallographica Section D* **67**:915–919 <https://doi.org/10.1107/S0907444911036225>
- Dupuy C, Ohayon R, Valent A, Noël-Hudson M-S, Dème D, Virion A. (1999) **Purification of a Novel Flavoprotein Involved in the Thyroid NADPH Oxidase** *Journal of Biological Chemistry* **274**:37265–37269 <https://doi.org/10.1074/jbc.274.52.37265>
- Emsley P, Lohkamp B, Scott WG, Cowtan K. (2010) **Features and development of iCoot** *Acta Crystallographica Section D* **66**:486–501 <https://doi.org/10.1107/S0907444910007493>
- Evans PR, Murshudov GN. (2013) **How good are my data and what is the resolution?** *Acta Crystallogr D Biol Crystallogr* **69**:1204–1214 <https://doi.org/10.1107/S0907444913000061>
- Fieschi F, Niviere V, Frier C, Decout JL, Fontecave M. (1995) **The mechanism and substrate specificity of the NADPH:flavin oxidoreductase from *Escherichia coli*** *The Journal of biological chemistry* **270**:30392–30400
- Gaudu P, Touati D, Niviere V, Fontecave M. (1994) **The NAD(P)H:flavin oxidoreductase from *Escherichia coli* as a source of superoxide radicals** *The Journal of biological chemistry* **269**:8182–8188
- Geiszt M, Kopp JB, Varnai P, Leto TL. (2000) **Identification of renox, an NAD(P)H oxidase in kidney** *Proc Natl Acad Sci U S A* **97**:8010–4
- Gekko K, Timasheff SN. (1981) **Mechanism of protein stabilization by glycerol: preferential hydration in glycerol-water mixtures** *Biochemistry* **20**:4667–4676 <https://doi.org/10.1021/bi00519a023>
- Gennaris A *et al.* (2015) **Repairing oxidized proteins in the bacterial envelope using respiratory chain electrons** *Nature* **528**:409–412 <https://doi.org/10.1038/nature15764>
- Hajjar C, Cherrier MV, Dias Mirandela G, Petit-Hartlein I, Stasia M-J, Fontecilla-Camps JC, Fieschi F, Dupuy J. (2017) **The NOX Family of Proteins Is Also Present in Bacteria** *mBio* **8** <https://doi.org/10.1128/mBio.01487-17>
- Han C-H, Nisimoto Y, Lee S-H, Kim ET, Lambeth JD. (2001) **Characterization of the Flavoprotein Domain of gp91phox Which Has NADPH Diaphorase Activity** *The Journal of Biochemistry* **129**:513–520 <https://doi.org/10.1093/oxfordjournals.jbchem.a002885>

- Hermoso JA, Mayoral T, Faro M, Gómez-Moreno C, Sanz-Aparicio J, Medina M. (2002) **Mechanism of coenzyme recognition and binding revealed by crystal structure analysis of ferredoxin-NADP+ reductase complexed with NADP+** *Journal of molecular biology* **319**:1133–1142 [https://doi.org/10.1016/S0022-2836\(02\)00388-1](https://doi.org/10.1016/S0022-2836(02)00388-1)
- Juillan-Binard C, Picciocchi A, Andrieu J-P, Dupuy J, Petit-Hartlein I, Caux-Thang C, Vivès C, Nivière V, Fieschi F. (2017) **A Two-component NADPH Oxidase (NOX)-like System in Bacteria Is Involved in the Electron Transfer Chain to the Methionine Sulfoxide Reductase MsrP** *Journal of Biological Chemistry* **292**:2485–2494 <https://doi.org/10.1074/jbc.M116.752014>
- Jumper J *et al.* (2021) **Highly accurate protein structure prediction with AlphaFold** *Nature* <https://doi.org/10.1038/s41586-021-03819-2>
- Kabsch W. (2010) **XDS** *Acta Crystallographica Section D* **66**:125–132 <https://doi.org/10.1107/S0907444909047337>
- Katoh K, Rozewicki J, Yamada KD. (2019) **MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization** *Briefings in Bioinformatics* **20**:1160–1166 <https://doi.org/10.1093/bib/bbx108>
- Kean KM, Carpenter RA, Pandini V, Zanetti G, Hall AR, Faber R, Aliverti A, Karplus PA. (2017) **High-resolution studies of hydride transfer in the ferredoxin:NADP+ reductase superfamily** *The FEBS journal* **284**:3302–3319 <https://doi.org/10.1111/febs.14190>
- Kikuchi H, Hikage M, Miyashita H, Fukumoto M. (2000) **NADPH oxidase subunit, gp91phox homologue, preferentially expressed in human colon epithelial cells** *Gene* **254**:237–243 [https://doi.org/10.1016/S0378-1119\(00\)00258-4](https://doi.org/10.1016/S0378-1119(00)00258-4)
- Koshkin V, Pick E. (1993) **Generation of superoxide by purified and relipidated cytochrome b559 in the absence of cytosolic activators** *FEBS letters* **327**:57–62
- Kovalevskiy O, Nicholls RA, Murshudov GN. (2016) **Automated refinement of macromolecular structures at low resolution using prior information** *Acta Crystallogr D Struct Biol* **72**:1149–1161 <https://doi.org/10.1107/S2059798316014534>
- Lalucque H, Silar P. (2003) **NADPH oxidase: an enzyme for multicellularity?** *Trends in Microbiology* **11**:9–12 [https://doi.org/10.1016/S0966-842X\(02\)00007-0](https://doi.org/10.1016/S0966-842X(02)00007-0)
- Liu R, Song K, Wu J-X, Geng X-P, Zheng L, Gao X, Peng H, Chen L. (2022) **Structure of human phagocyte NADPH oxidase in the resting state** *eLife* **11** <https://doi.org/10.7554/eLife.83743>
- Magnani F, Nenci S, Millana Fananas E, Ceccon M, Romero E, Fraaije MW, Mattevi A. (2017) **Crystal structures and atomic model of NADPH oxidase** *Proceedings of the National Academy of Sciences* **114**:6764–6769 <https://doi.org/10.1073/pnas.1702293114>
- Mariaule V, Dupeux F, Márquez JA. (2014) **Estimation of crystallization likelihood through a fluorimetric thermal stability assay** *Methods Mol Biol* **1091**:189–195 https://doi.org/10.1007/978-1-62703-691-7_13
- Márquez JA, Cipriani F. (2014) **CrystalDirectTM: A Novel Approach for Automated Crystal Harvesting Based on Photoablation of Thin Films In: Chen YW, editor. Structural Genomics: General Applications. Totowa NJ: Humana Press :197–203** https://doi.org/10.1007/978-1-62703-691-7_14

- Martin J, Robert X, Gouet P, Falson P, Chaptal V. (2023) **Specific Xray diffraction patterns of membrane proteins caused by secondary structure collinearity** *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1865** <https://doi.org/10.1016/j.bbamem.2022.184065>
- Martins de Oliveira V, Godoi Contessoto V de, da Silva F Bruno, Caetano DL Zago, de Carvalho S Jurado, Leite VB. Pereira (2018) **Effects of pH and Salt Concentration on Stability of a Protein G Variant Using Coarse-Grained Models** *Biophysical Journal* **114**:65–75 <https://doi.org/10.1016/j.bpj.2017.11.012>
- Massari M, Nicoll CR, Marchese S, Mattevi A, Mascotti ML. (2022) **Evolutionary and structural analyses of the NADPH oxidase family in eukaryotes reveal an initial calcium dependency** *Redox Biology* **56** <https://doi.org/10.1016/j.redox.2022.102436>
- McCarthy AA *et al.* (2018) **ID30B – a versatile beamline for macromolecular crystallography experiments at the ESRF** *J Synchrotron Rad* **25**:1249–1260 <https://doi.org/10.1107/S1600577518007166>
- McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. (2007) **Phaser crystallographic software** *J Appl Crystallogr* **40**:658–674 <https://doi.org/10.1107/S0021889807021206>
- Monaco S *et al.* (2013) **Automatic processing of macromolecular crystallography X-ray diffraction data at the ESRF** *J Appl Cryst* **46**:804–810 <https://doi.org/10.1107/S0021889813006195>
- Murshudov GN, Vagin AA, Dodson EJ. (1997) **Refinement of Macromolecular Structures by the Maximum-Likelihood Method** *Acta Crystallographica Section D* **53**:240–255 <https://doi.org/10.1107/S0907444996012255>
- Musset B, Clark RA, DeCoursey TE, Petheo GL, Geiszt M, Chen Y, Cornell JE, Eddy CA, Brzyski RG, Jamali AE. (2012) **NOX5 in Human Spermatozoa: EXPRESSION, FUNCTION, AND REGULATION *** *Journal of Biological Chemistry* **287**:9376–9388 <https://doi.org/10.1074/jbc.M111.314955>
- Nisimoto Y, Diebold BA, Constantino-Gomes D, Lambeth JD. (2014) **Nox4: a hydrogen peroxide-generating oxygen sensor** *Biochemistry* **53**:5111–5120 <https://doi.org/10.1021/bi500331y>
- Nisimoto Y, Jackson HM, Ogawa H, Kawahara T, Lambeth JD. (2010) **Constitutive NADPH-dependent electron transferase activity of the Nox4 dehydrogenase domain** *Biochemistry* **49**:2433–2442 <https://doi.org/10.1021/bi9022285>
- Nisimoto Y, Motalebi S, Han CH, Lambeth JD. (1999) **The p67(phox) activation domain regulates electron flow from NADPH to flavin in flavocytochrome b(558)** *The Journal of biological chemistry* **274**:22999–23005
- Nisimoto Y, Ogawa H, Miyano K, Tamura M. (2004) **Activation of the flavoprotein domain of gp91phox upon interaction with N-terminal p67phox (1-210) and the Rac complex** *Biochemistry* **43**:9567–9575 <https://doi.org/10.1021/bi0400249>
- Niviere V, Fieschi F, Decout JL, Fontecave M. (1996) **Is the NAD(P)H:flavin oxidoreductase from Escherichia coli a member of the ferredoxin-NADP+ reductase family?. Evidence for the catalytic role of serine 49 residue** *The Journal of biological chemistry* **271**:16656–16661

- Noreng S *et al.* (2022) **Structure of the core human NADPH oxidase NOX2** *Nat Commun* **13** <https://doi.org/10.1038/s41467-022-33711-0>
- O'Neill S, Mathis M, Kovačič L, Zhang S, Reinhardt J, Scholz D, Schopfer U, Bouhelal R, Knaus UG. (2018) **Quantitative interaction analysis permits molecular insights into functional NOX4 NADPH oxidase heterodimer assembly** *Journal of Biological Chemistry* **293**:8750–8760 <https://doi.org/10.1074/jbc.RA117.001045>
- Page CC, Moser CC, Chen X, Dutton PL. (1999) **Natural engineering principles of electron tunnelling in biological oxidation-reduction** *Nature* **402**:47–52 <https://doi.org/10.1038/46972>
- Pei J, Kim B-H, Grishin NV. (2008) **PROMALS3D: a tool for multiple protein sequence and structure alignments** *Nucleic Acids Research* **36**:2295–2300 <https://doi.org/10.1093/nar/gkn072>
- Piccicocchi A, Debeurme F, Beaumel S, Dagher M-C, Grunwald D, Jesaitis AJ, Stasia M-J. (2011) **Role of putative second transmembrane region of Nox2 protein in the structural stability and electron transfer of the phagocytic NADPH oxidase** *Journal of Biological Chemistry* **286**:28357–28369 <https://doi.org/10.1074/jbc.M111.220418>
- Piubelli L, Aliverti A, Arakaki AK, Carrillo N, Ceccarelli EA, Karplus PA, Zanetti G. (2000) **Competition between C-terminal Tyrosine and Nicotinamide Modulates Pyridine Nucleotide Affinity and Specificity in Plant Ferredoxin-NADP+ Reductase*** *Journal of Biological Chemistry* **275**:10472–10476 <https://doi.org/10.1074/jbc.275.14.10472>
- Rae J, Newburger PE, Dinauer MC, Noack D, Hopkins PJ, Kuruto R, Curnutte JT. (1998) **X-Linked Chronic Granulomatous Disease: Mutations in the CYBB Gene Encoding the gp91-phox Component of Respiratory-Burst Oxidase** *The American Journal of Human Genetics* **62**:1320–1331 <https://doi.org/10.1086/301874>
- Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. (1996) **Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone** *J Clin Invest* **97**:1916–1923 <https://doi.org/10.1172/JCI118623>
- Robert X, Kassis-Sahyoun J, Ceres N, Martin J, Sawaya MR, Read RJ, Gouet P, Falson P, Chaptal V. (2017) **X-ray diffraction reveals the intrinsic difference in the physical properties of membrane and soluble proteins** *Sci Rep* **7** <https://doi.org/10.1038/s41598-017-17216-1>
- Segal AW, Jones OT. (1978) **Novel cytochrome b system in phagocytic vacuoles of human granulocytes** *Nature* **276**:515–517
- Segal AW, Jones OTG. (1979) **The subcellular distribution and some properties of the cytochrome b component of the microbicidal oxidase system of human neutrophils** *Biochemical Journal* **182**:181–188 <https://doi.org/10.1042/bj1820181>
- Sharpe HJ, Stevens TJ, Munro S. (2010) **A Comprehensive Comparison of Transmembrane Domains Reveals Organelle-Specific Properties** *Cell* **142**:158–169 <https://doi.org/10.1016/j.cell.2010.05.037>
- Shpungin S, Dotan I, Abo A, Pick E. (1989) **Activation of the Superoxide Forming NADPH Oxidase in a Cell-free System by Sodium Dodecyl Sulfate** *Journal of Biological Chemistry* **264**:9195–9203 [https://doi.org/10.1016/S0021-9258\(18\)60513-7](https://doi.org/10.1016/S0021-9258(18)60513-7)

- Skubák P, Pannu NS. (2013) **Automatic protein structure solution from weak X-ray data** *Nat Commun* **4** <https://doi.org/10.1038/ncomms3777>
- Srinivasan B. (2022) **A guide to the Michaelis-Menten equation: steady state and beyond** *The FEBS Journal* **289**:6086–6098 <https://doi.org/10.1111/febs.16124>
- Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, Lambeth JD. (1999) **Cell transformation by the superoxide-generating oxidase Mox1** *Nature* **401**:79–82
- Sun J. (2020) **Structures of mouse DUOX1–DUOXA1 provide mechanistic insights into enzyme activation and regulation** *Nat Struct Mol Biol* <https://doi.org/10.1038/s41594-020-0501-x>
- Taylor WR, Jones DT, Segal AW. (1993) **A structural model for the nucleotide binding domains of the flavocytochrome b-245 beta-chain** *Protein science : a publication of the Protein Society* **2**:1675–85
- Vermot A *et al.* (2020) **Interdomain Flexibility within NADPH Oxidase Suggested by SANS Using LMNG Stealth Carrier** *Biophysical Journal* **S 6349520305191** <https://doi.org/10.1016/j.bpj.2020.06.025>
- Vermot A, Petit-Härtlein I, Smith SME, Fieschi F. (2021) **NADPH Oxidases (NOX): An Overview from Discovery** *Molecular Mechanisms to Physiology and Pathology. Antioxidants* **10** <https://doi.org/10.3390/antiox10060890>
- Ward J, Zhang S, Sikora A, Michalski R, Yin Y, D’Alessio A, McLoughlin RM, Jaquet V, Fieschi F, Knaus UG. (2023) **VEO-IBD NOX1 variant highlights a structural region essential for NOX/DUOX catalytic activity** *Redox Biology* **102905** <https://doi.org/10.1016/j.redox.2023.102905>
- Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. (2009) **Jalview Version 2--a multiple sequence alignment editor and analysis workbench** *Bioinformatics* **25**:1189–1191 <https://doi.org/10.1093/bioinformatics/btp033>
- Winn MD, Cowtan KD, Dodson EJ, Evans PR, Keegan RM, Leslie AGW, McCoy A. (2011) **Overview of the CCP4 suite and current developments**
- Wu J-X, Liu R, Song K, Chen L. (2021) **Structures of human dual oxidase 1 complex in low-calcium and high-calcium states** *Nat Commun* **12** <https://doi.org/10.1038/s41467-020-20466-9>
- Yang J, Zhang Y. (2015) **I-TASSER server: new development for protein structure and function predictions** *Nucleic Acids Res* **43**:W174–W181 <https://doi.org/10.1093/nar/gkv342>
- Zander U *et al.* (2016) **Automated harvesting and processing of protein crystals through laser photoablation** *Acta Cryst D* **72**:454–466 <https://doi.org/10.1107/S2059798316000954>
- Zhang X, Krause K-H, Xenarios I, Soldati T, Boeckmann B. (2013) **Evolution of the Ferric Reductase Domain (FRD) Superfamily: Modularity, Functional Diversification, and Signature Motifs** *PloS one* **8** <https://doi.org/10.1371/journal.pone.0058126.s005>
- Zhen L, Yu L, Dinauer MC. (1998) **Probing the role of the carboxyl terminus of the gp91phox subunit of neutrophil flavocytochrome b558 using site-directed mutagenesis** *The Journal of biological chemistry* **273**:6575–6581

Article and author information

Isabelle Petit-Härtlein

Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale, Grenoble, France

Annelise Vermot

Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale, Grenoble, France

ORCID iD: [0000-0003-0142-4887](https://orcid.org/0000-0003-0142-4887)

Michel Thépaut

Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale, Grenoble, France

ORCID iD: [0000-0003-4792-8271](https://orcid.org/0000-0003-4792-8271)

Anne Sophie Humm

European Molecular Biology Laboratory (EMBL) Grenoble, 71 Avenue des Martyrs, Grenoble, France

Florine Dupeux

Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale, Grenoble, France, European Molecular Biology Laboratory (EMBL) Grenoble, 71 Avenue des Martyrs, Grenoble, France

ORCID iD: [0000-0001-9532-5374](https://orcid.org/0000-0001-9532-5374)

Jérôme Dupuy

Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale, Grenoble, France

ORCID iD: [0000-0002-2721-5365](https://orcid.org/0000-0002-2721-5365)

Vincent Chaptal

CNRS-Lyon 1 University Laboratory 5086, IBCP, Lyon, France

ORCID iD: [0000-0003-2603-0294](https://orcid.org/0000-0003-2603-0294)

José A. Marquez

European Molecular Biology Laboratory (EMBL) Grenoble, 71 Avenue des Martyrs, Grenoble, France, ALPX S.A.S. 71, Avenue des Martyrs, Grenoble, France

ORCID iD: [0000-0002-3453-9261](https://orcid.org/0000-0002-3453-9261)

Susan M.E. Smith

Department of Molecular and Cellular Biology, Kennesaw State University, GA, USA

For correspondence: ssmit325@kennesaw.edu

Franck Fieschi

Institut Universitaire de France (IUF), Paris, France

For correspondence: franck.fieschi@ibs.fr

ORCID iD: [0000-0003-1194-8107](https://orcid.org/0000-0003-1194-8107)

Copyright

© 2024, Petit-Härtlein et al.

This article is distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use and redistribution provided that the original author and source are credited.

Editors

Reviewing Editor

Volker Dötsch

Goethe University, Frankfurt am Main, Germany

Senior Editor

Volker Dötsch

Goethe University, Frankfurt am Main, Germany

Reviewer #1 (Public Review):

Summary:

The manuscript describes the crystal structures of *Streptococcus pneumoniae* NOXs. Crystals were obtained for the wild-type and mutant dehydrogenase domain, as well as for the full-length protein comprising the membrane domain. The manuscript further carefully studies the enzyme's kinetics and substrate-specificity properties. *Streptococcus pneumoniae* NOX is a non-regulated enzyme, and therefore, its structure should provide a view of the NOX active conformation. The structural and biochemical data are discussed on this ground.

Strengths:

This is very solid work. The protein chemistry and biochemical analysis are well executed and carefully described. Similarly, the crystallography must be appreciated given the difficulty of obtaining good enzyme preparations and the flexibility of the protein. Even if solved at medium resolution, the crystal structure of the full-length protein conveys relevant information. The manuscript nicely shows that the domain rotations are unlikely to be the main mechanistic element of NOX regulation. It rather appears that the NADPH-binding conformation is pivotal to enzyme activation. The paper extensively refers to the previous literature and analyses the structures comprehensively with a comparison to previously reported structures of eukaryotic and prokaryotic NOXs.

<https://doi.org/10.7554/eLife.93759.2.sa1>

Reviewer #2 (Public Review):

The authors describe the structure of the *S. pneumoniae* Nox protein (SpNOX). This is a first. The relevance of it to the structure and function of eukaryotic Noxes is discussed in depth.

One of the strengths of this work is the effort put into preparing a pure and functionally active SpNOX preparation. The protein was expressed in *E. coli* and the purification and optimization of its thermostability and activity are described in detail, involving salt concentration, glycerol concentration, and pH.

Comments on revised version:

This reviewer would like to compliment the authors for the conscientious revision of the manuscript. Their response to the comments and the detailed explanations of the issues that did not appear clear enough to the reviewer are much appreciated. Their reaction to the review was not only superbly competent but also prominently good natured.

The revised version is perfect and represents a major contribution to our understanding of the molecular details of Nox function. As for the questions not yet answered, I shall quote the authors: "Time will tell".

<https://doi.org/10.7554/eLife.93759.2.sa0>

Author Response

The following is the authors' response to the original reviews.

Public Reviews:

Reviewer #1 (Public Review):

Summary:

The manuscript describes the crystal structures of Streptococcus pneumoniae NOXs. Crystals were obtained for the wild-type and mutant dehydrogenase domain, as well as for the full-length protein comprising the membrane domain. The manuscript further carefully studies the enzyme's kinetics and substrate-specificity properties. Streptococcus pneumoniae NOX is a non-regulated enzyme, and therefore, its structure should provide a view of the NOX active conformation. The structural and biochemical data are discussed on this ground.

Strengths:

This is very solid work. The protein chemistry and biochemical analysis are well executed and carefully described. Similarly, the crystallography must be appreciated given the difficulty of obtaining good enzyme preparations and the flexibility of the protein. Even if solved at medium resolution, the crystal structure of the full-length protein conveys relevant information. The manuscript nicely shows that the domain rotations are unlikely to be the main mechanistic element of NOX regulation. It rather appears that the NADPH-binding conformation is pivotal to enzyme activation. The paper extensively refers to the previous literature and analyses the structures comprehensively with a comparison to previously reported structures of eukaryotic and prokaryotic NOXs.

We thank the referee for these very nice comments about our work.

Weaknesses:

The manuscript is not always very clear with regard to the analysis of NADPH binding. The last section describes a "crevice" featured by the NADPH-binding sites in NOXs. It remains unclear whether this element corresponds to the different conformations of the protein C-terminal residues or more extensive structural differences. This point must be clarified.

We agree with the referee that our terminology was not very clear. Responding to your comment helped us to improve our explanation: we have changed the text to emphasize the differences we observe in the distances between the FAD binding groove and the entire NADPH binding groove, which includes conserved NADPH-contacting motifs as well as the critical aromatic.

A second less convincing point concerns the nature of the electron acceptor. The manuscript states that this NOX might not physiologically act as a ROS producer. A question then immediately arises: Is this protein an iron reductase?

Can the authors better discuss or provide more data about this point?

The referee has a legitimate point, which was also our first idea. In the initial work on SpNOX, where we discovered bacterial NOX enzymes (see Hajjar et al 2017 in mBio), we evaluated its possible role as an iron reductase. There we showed that SpNOX can reduce CytC directly; however, while some reduction of Fe³⁺-NTA complex (used classically in ferric reductase activity assay) occurred, this reduction was inhibitable by SOD and occurred indirectly by the superoxide produced, so therefore not a true iron reductase activity. This represents a mixed situation of direct and indirect reduction of an iron-containing acceptor that appears to preclude physiological iron reductase activity since it appears that the protein component of CytC allows it to interact with SpNOX. As these questions had been already addressed in a previous paper, we did not add anything here and we prefer to underline this possibility of another acceptor and to leave this question open for future works.

Reviewer #2 (Public Review):

*The authors describe the structure of the *S. pneumoniae* Nox protein (SpNOX). This is a first. The relevance of it to the structure and function of eukaryotic Noxes is discussed in depth.*

Strengths and Weaknesses

*One of the strengths of this work is the effort put into preparing a pure and functionally active SpNOX preparation. The protein was expressed in *E. coli* and the purification and optimization of its thermostability and activity are described in detail, involving salt concentration, glycerol concentration, and pH.*

This reviewer was surprised by the fact that the purification protocol in the eLife paper differs from those in the mBio and Biophys. J. papers by the absence of the detergent lauryl maltose neopentyl glycol (LMNG). LMNG is only present in the activity assay at a low concentration (0.003%; molar data should be given; by my calculation, this corresponds to 30 μM).

We regret this misunderstanding: our description was not clear enough. As the referee points out, in previous papers we purified the full length SpNOX with the detergent LMNG. In the current paper, we described only the protocol for SpNOX DH domain variant, a soluble cytoplasmic domain. We have now modified the text to clarify the difference between the purification of fulllength SpNOX variants, which were performed with detergent as cited in Vermot et al 2020, and the purification of DH domains, which are soluble and thus did not require detergent in the purification.

In light of the presence of lipids in cryo-EM-solved structures of DUOX and NOX2, it is surprising that the authors did not use reconstitution of the purified SpNOX in phospholipid (nanodisk?). The issue is made more complicated by the statement on p. 18 of "structures solved in detergent like ours" when no use of detergent in the solubilization and purification of SpNOX is mentioned in the Methods section (p. 21-22).

As stated above, detergent used to purify the full-length version of SpNOX. We did in fact perform some preliminary tests of reconstitution in nanodiscs. Different trials of negative staining studies showed heterogeneous size of SpNOX in nanodiscs and the initial images were not promising. Furthermore, in parallel, we had positive results in crystallography relatively quickly with protein in detergent. We thus focused on refining the crystals, which was a fairly long and mobilizing task; we decided to allocate time and resources to the promising avenue and did not further pursue nanodiscs.

We did not go in the Cryo-EM direction because the small size of the protein was initially believed to be a significant barrier to successful Cryo-EM. Perhaps we could have pursued this avenue: while our manuscript here was submitted to eLife, another group deposited a preprint in BioRxiv using CryoEM to solve the structure of SpNOX (see comment below). This structure was solved in detergent so even in this CryoEM structure there is no information on the potential roles of lipids as asked by the referee.

In this revised version, we have added a comment, in the last paragraph, in reference to the additional data available today thanks to the other structures generated by this other group (Murphy's group).

Can the authors provide information on whether E. coli BL21 is sufficiently equipped for the heme synthesis required for the expression of the TM domain of SpNOX. Was supplementation with δ -aminolevulinic acid used

The production of His-SpNox in E.coli C41(DE3) is without any δ -aminolevulinic acid supplementation. Supplementation was tested but no change was observed regarding the heme content (UV/Visible spectra) so we settled on the purification described by Vermot et al 2020. Initially, for the mBio paper (Haajar et al 2017), we performed heme titrations which gave stoichiometry between 1.35 to 1.5 heme/protein, indicating 2 hemes (these data were not shown). In the end in this work we observed two hemes in the crystal structure, thus confirming that E.coli, at least for this protein, did not need supplementation with δ -aminolevulinic acid.

The 3 papers on SpNOX present more than convincing evidence that SpNOX is a legitimate Nox that can serve as a legitimate model for eukaryotic Noxes (cyanide resistance, inhibition by DPI, absolute FAD dependence, and NADPH/NADH as the donor or electrons to FAD). It is also understood that the physiological role of SpNOX in S. pneumoniae is unknown and that the fact that it can reduce molecular oxygen may be an experimental situation that does not occur in vivo.

I am, however, linguistically confused by the statement that "SpNOX requires "supplemental" FAD". Noxes have FAD bound non-covalently and this is the reason that, starting from the key finding of Babior on NOX2 back in 1977 to the present, FAD has to be added to in vitro systems to compensate for the loss of FAD in the course of the purification of the enzyme from natural sources or expression in a bacterial host. I wonder whether this makes FAD more of a cosubstrate than a prosthetic group unless what the authors intend to state is that SpNOX is not a genuine flavoprotein.

We believe there is some confusion between SpNOX – the full length transmembran protein -- and SpNOXDH -- the cytosolic domain only. The sentence pinpointed by the referee was in fact "The strict requirement of FAD addition for SpNOXDH activity suggests that the flavin behaves as a cosubstrate". This statement was about the isolated cytosolic domain that does not contain the TM part of the protein.

We agree that in WT NOX enzymes (including SpNOX) FAD is held within the enzyme structure and thus can be considered, by definition, as a prosthetic group. This is supported by the nanomolar affinity for FAD of SpNOX. We did not intend to say that NOX and SpNOX are not genuine flavoproteins.

On the other hand, when isolated, the affinity of DH domain for flavins drops to the μ M level. This μ M level of affinity does not allow stable maintenance of the flavin in the active site as illustrated by the spectra of Figure 3. This is instead the typical affinity of a substrate or a co-substrate (similar to that of substrate NADPH) that can be exchangeable and diffuse in and out of the active site. The DH domain recognizes and reduces flavins but, as a consequence of

its lower affinity, will release to its environment free reduced flavins. Thus the isolated DH behaves as a flavin reductase that uses flavin as substrate. Such enzymes have already been well described (and some of them are of the FNR family). Such enzymes, using flavin as substrate, typically have affinity for flavin in the μM range and share with the SpNOX DH binding properties centered on the isoalloxazine ring only.

We understand that, in the text, to switch from the SpNOX to the SpNOX DH and for FAD from a prosthetic group to a diffusible co-substrate can be confusing. So, to make it clearer, we modified the following sentences and added references to “some flavin reductases characterization” that could provide support for the reader.

“The strict requirement of FAD addition for SpNOXDH activity and its μM level of affinity suggests that the flavin behaves as a co-substrate rather than a prosthetic group. As an isolated domain, SpNOXDH may work as a flavin reductase enzyme (Gaudu et al, 1994; Fieschi et al 1995; Nivière et al 1996), ..”

We hope that it will help.

I am also puzzled by the statement that SpNOX "does not require the addition of Cyt c to sustain superoxide production". Researchers with a Cartesian background should differentiate between cause and effect. Cyt c serves merely as an electron acceptor from superoxide made by SpNOX but superoxide production and NADPH oxidation occur independently of the presence of added Cyt c.

Thanks to the referee for pointing out this poor wording. We agree and have amended the text to clarify what we originally meant. It is now:

“SpNOXDH requires supplemental FAD to sustain both superoxide production, which can be observed in the presence of Cyt c (Figure 2A), and NADPH oxidation, which can be observed in the absence of Cyt c (Figure 2B).”

The ability of the DH domain of SpNOX (SpNOXDH) to produce superoxide is surprising to this reviewer. The result is based on the inhibition of Cyt c reduction by added superoxide dismutase (SOD) by 40%. In all eukaryotic Noxes superoxide is produced by the one-electron reduction of molecular oxygen by electrons originating from the distal heme, having passed from reduced FAD via two hemes. The proposal that superoxide is generated by direct transfer of electrons from FAD to oxygen deserves a more in-depth discussion and relies too heavily on the inhibitory effect of SOD. A control experiment with inactivated SOD should have been done (SOD is notoriously heat resistant and inactivation might require autoclaving).

The initial reports of a NOX DH-domain-only construct (that of human Nox4) producing superoxide are cited in the text. Moreover, natural flavin reductases are known to produce superoxide due to the release of free reduced flavin in the medium.

As explain above, FAD in full length SpNox is a relay for the electrons from NADPH to heme and is internal to the protein and thus devoted to this specific task.

In the case of SpNOX DH, its flavin reductase behavior leads to the release in the medium of free reduced flavin as a nonspecific diffusible electron carrier. It has been already demonstrated that such free reduced flavin can efficiently reduce soluble O₂ and be a source of superoxide.


This has been particularly well documented in (Gaudu et al, 1994. J.Biol.Chem). We have added this reference to the text (see the modified sentence in a reply, 2 comments above).

Furthermore, we want to point to the referee that the link between flavin and superoxide production here is not only based on the inhibition by SOD. When we added the flavin inhibitor DPI we observed no more superoxide production from the DH domain (Figure 2C). This supports the role of free-reduced flavin in both the production of superoxide and also part of direct cyt C reduction as observed.

An unasked and unanswered question is that, since under aerobic conditions, both direct Cyt c reduction (60%) and superoxide production (40%) occur, what are the electron paths responsible for the two phenomena occurring simultaneously?

We thank the referee for dedication to a clear understanding of the mechanism used by the SpNOXDH construct. It pushes us to develop a clear description of the mechanism at work here for the readers. Please find below a proposal mechanism describing the electron transfer from NAD(P)H to free flavin that can, as diffusible species, then reduce non-specifically either the O₂ or the Cyt.C encountered.

Author response image 1.



However, it is important to remember that this is not physiological, and rather the result of using a DH domain isolated from the TM of SpNOX. Nonetheless, it shows that the DH domain is fully functional for NAD(P)H as well as the hydride transfer.

*This reviewer had difficulty in following the argument that the fact that the *k_{cat}* of SpNOX and SpNOXDH are similar supports the thesis that the rate of enzyme activation is dependent on hydride transfer from nicotinamide to FAD.*

We have amended the text to clarify this point. If the reaction rate is not affected by the presence or absence of the hemes in the TM domain, this inevitably implies that the rate is NOT limited by the electron transfer to the heme, and ultimately to O₂, from the FAD, and thus the hydride transfer step that oxidizes the FAD must be the rate limiting step.

The section dealing with mutating F397 is a key part of the paper. There is a proper reference to the work of the Karplus group on plant FNRs (Deng et al). However, later work, addressing comparison with NOX2, should be cited (Kean et al., FEBS J., 284, 3302-

3319, 2017). Also, work from the Dinauer group on the minimal effect of mutating or deleting the C-terminal F570 in NOX2 on superoxide production should be cited (Zhen et al., J. Biol. Chem. 273, 6575-6581, 1998).

We thank the reviewer for pointing out our unintended omission of these important works; we have amended the text and added the citations.

It is not clear why mutating F397 to W (both residues having aromatic side chains) would stabilize FAD binding.

In a few words, trp's double ring can establish larger and stronger vanderWaals contact with the isoalloxazine ring than the phe sidechain. Our discussion regarding this point is extensive in the structural section where we compare the structures with F and W in this position. At this time we do not think it is necessary to add anything to the text.

Also, what is meant by "locking the two subdomains of the DH domain"? What subdomains are meant?

The two subdomains are the NADPH-binding domain and the FAD-binding domain, which we define on p 11 ("SpNOXDH presents a typical fold of the FNR superfamily of reductase domain containing two sub-domains, the FAD-binding domain (FBD) and an NADPH-binding domain (NBD) ") and which are labeled in Fig. 4. By "locking" we meant to convey immobilizing them into a specific conformation; we have amended the text to clarify this point.

Methodological details on crystallization (p. 11) should be delegated to the Methodology section. How many readers are aware that SAD means "Single Wavelength Anomalous Diffraction" or know what is the role of sodium bromide?

We have amended the text to emphasize the intended point, which is the different origins of the two DH structures: the de novo structure was possible through co crystallization with bromide, and the molecular replacement structure used the de novo structure as a model.

The data on the structure of SpNOX are supportive of a model of Nox activation that is "dissident" relative to the models offered for DUOX and NOX2 activation. These latter models suggested that the movement of the DH domain versus the TM domain was related to conversion from the resting to the activated state. The findings reported in this paper show that, unexpectedly, the domain orientation in SpNOX (constitutively active!) is much closer to that of resting NOX2. One of the criteria associated with the activated state in Noxes was the reduction of the distance between FAD and the proximal heme. The authors report that, paradoxically, this distance is larger in the constitutively active SpNOX (9.2 Å) than that in resting state NOX2 (7.6 Å) and the distance in Ca2+-activated DUOX is even larger (10.2 Å).

A point made by the authors is the questioning of the paradigm that activation of Noxes requires DH domain motion.

Instead, the authors introduce the term "tensing", within the DH domain, from a "relaxed" to a more rigid conformation. I believe that this proposal requires a somewhat clearer elaboration

It is clear that the distance between the FAD and NADPH shown in the Duox and Nox2 structures is too large for the chemical reaction of hydride transfer. Wu et al used the terms 'tense' and 'relaxed' to describe conformations of the DH domain corresponding to 'short distance' and 'longer distance', respectively, between the two ligand binding sites. We quoted

this terminology and have amended the text to clarify that we envision a motion of the NBD relative to the FBD, as distinct from a larger motion of the whole DH domain relative to the TM domain.

The statement on p. 18, in connection to the phospholipid environment of Noxes, that the structure of SpNOX was "solved in detergent" is puzzling since the method of SpNOX preparation and purification does not mention the use of a detergent. As mentioned before, this absence of detergent in the present report was surprising because LMNG was used in the methods described in the mBio and Biophys. J. papers. The only mention of LMNG in the present paper was as an addition at a concentration of 0.003% in the activity assay buffers.

Please see our response to similar points above. Detergent was present for the solubilization of the full-length SpNOX.

The Conclusions section contains a proposal for the mechanism of conversion of NOX2 from the resting to the activated state. The inclusion of this discussion is welcome but the structural information on the constitutively active SpNOX can, unfortunately, contribute little to solving this important problem. The work of the Lambeth group, back in 1999 (cited as Nisimoto et al.), on the role of p67-phox in regulating hydride transfer from NADPH to FAD in NOX2 may indeed turn out to have been prophetic. However, only solving the structure of the assembled NOX2 complex will provide the much-awaited answer. The heterodimerization of NOX2 with p22-phox, the regulation of NOX2 by four cytosolic components, and the still present uncertainty about whether p67-phox is indeed the final distal component that converts NOX2 to the activated state make this a formidable task.

The work of the Fieschi group on SpNOX is important and relevant but the absence of external regulation, the absence of p22-phox, and the uncertainty about the target molecule make it a rather questionable model for eukaryotic Noxes. The information on the role of the C-terminal Phe is of special value although its extension to the mechanism of eukaryotic Nox activation proved, so far, to be elusive.

We really thank the referee for the positive comments on our work and the deep interest shown by this careful evaluation.

We understand the arguments of the referee regarding the relevance of our work here to eukaryotic NOX, but we do not share the reservations expressed. While human NOXes need interactions with other proteins or have EF-hand or other domains that control them, SpNOX corresponds exactly to the minimal core common to any NOX isoform. In fact, because SpNOX has only this conserved core, it is unique in that it can work as a constitutively active NOX without protein-protein interactions or regulatory domains. Thus the fundamentals of electron transfer mechanisms of NOX enzyme are present in SpNOX.

There might be some differences in the internal organization from isoform to isoform (as regarding the relative DH domain vs TM domain orientation) but considering the similarity between NOX2 and SpNOX topology we are rather confident that the SpNOX structure will turn out to be a reasonable model of the activated NOX2 structure. History will tell.

In any case, this work on SpNOX allowed us to highlight hydride transfer as the limiting step and also to highlight some structural differences that could be at the source of the regulation in eukaryotic NOX. In itself, we think this is a significant contribution to the field.

We warmly thank both referees for their constructive remarks and their help in the improvement of this manuscript.

Recommendations for the authors:

Reviewer #1 (Recommendations For The Authors):

- *The manuscript states that the flavin "behaves" like a co-substrate and thereby reports on the K_m for the flavins. I feel that this terminology might be confusing. The flavin is unchanged after the reaction, and what matters is the enzyme's affinity for the flavin and the flavin concentration needed to saturate the enzyme (to have it in the fully holo form).*

See above -- answering many questions from referee2, we have extensively commented on that point (substrate, cofactor, affinity, etc..) and made some adjustments in the text to clarify. We hope it is now satisfactory.

- *I could not find the methodological description of the experiments performed to measure the K_m for the flavins, and the legend of Figure S4 does not help in this regard. I think that the data (left panels of S4) should be interpreted as binding curves with associated K_d values.*

We have changed the text to clarify the method used to measure K_m for flavins.

- *A related point is that the manuscript refers to K_m as an "affinity". This is inappropriate and should be avoided, as the K_m is not the K_d .*

We agree with the referee that the K_m is not the K_d . However, under the appropriate conditions, to which our experiments conform, K_m is accepted as a relevant approximation of affinity (Srinivasan, FEBS Journal, v 289 pp 6086-6098 2022). We have added a sentence to clarify this point and cite this reference in the text.

- *The environment around the putative oxygen site should be shown. The text indicates that "the residues characteristic of the O_2 reducing center in eukaryotic FRD domains of NOX and DUOX enzymes are not conserved in SpNOX." How does the site look? This point relates to the more general comment above on the oxidizing substrate used by this bacterial NOX.*

This is a really interesting point that contains many potential biological developments for future studies of this prokaryotic family of NOX enzymes. While we were submitting this work to eLife for evaluation, another group (Murphy's lab) filed a pre-publication in BioRxiv, in which they also solved the structure of SpNOX but this time by CryoEM with an unexpected level of resolution for such a small protein (their paper is not yet published but probably under peer review somewhere). In their work, they made a special effort to identify the O_2 reducing center (bacterial NOX sequences alignment, mutation studies, ...) They were not able to localize such a site with accuracy. There is also other complementary data between their work and ours. So, we will add a paragraph at the end of the discussion to comment on this parallel work and to emphasize on the complementarity of their studies and what it brings to the final understanding of this enzyme.

- *The section "A Close-up View of NOX's NAD(P)H Binding Domains vs the FNR Gold Standard" should be clarified.*

I found it difficult to understand. Is the different conformation of Phe397 creating the crevice? Could NADPH be modeled in NOX2 and DUOX in the same conformation observed in

FNR and modeled in the bacterial NOX? Or would there be clashes, implying the necessity of larger conformational changes to bring the nicotinamide closer to the FAD?

Please see responses above on this point; we have amended the text to clarify. In a few words, we propose that activation in the eukaryotic enzymes would entail NBD subdomain (containing NADPH site) towards the FBD subdomain (containing FAD) through an internal motion within the DH domain. Doing so, they would approach the DH domain topology of SpNOX, which models an active state.

Reviewer #2 (Recommendations For The Authors):

On p. 6, second line, it should be (Figure 1C and 1D). Space is missing between C and "and".

On p. 9, in Figure 3, the labeling A and B are missing. Also, the legend of part B does not correspond to the actual graph colors. Thus, the tracing of F397W is red and not grey as indicated in the legend.

Corrected. Thank you